0001213900-21-024692.txt : 20210505 0001213900-21-024692.hdr.sgml : 20210505 20210505161633 ACCESSION NUMBER: 0001213900-21-024692 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210505 DATE AS OF CHANGE: 20210505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inmune Bio, Inc. CENTRAL INDEX KEY: 0001711754 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 475205835 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38793 FILM NUMBER: 21893512 BUSINESS ADDRESS: STREET 1: 1200 PROSPECT STREET STREET 2: SUITE 525 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 8589643720 MAIL ADDRESS: STREET 1: 1200 PROSPECT STREET STREET 2: SUITE 525 CITY: LA JOLLA STATE: CA ZIP: 92037 10-Q 1 f10q0321_inmunebio.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

INMUNE BIO INC.

(Exact name of registrant as specified in its charter)

Nevada		47-5205835
(State of incorporation)		(I.R.S. Employer Identification No.)

David Moss

1200 Prospect Street, Suite 525

La Jolla, CA 92037

(Address of principal executive office) (Zip code)

(858) 964-3720

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period than the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		INMB		The NASDAQ Stock Market LLC

As of May 5, 2021, there were 14,932,638 shares of our common stock, par value $0.001 per share, outstanding.

INMUNE BIO INC.

FORM 10-Q

FOR THE THREE MONTHS ENDED MARCH 31, 2021

INDEX

PART I – FINANCIAL INFORMATION		1

Item 1.	Financial Statements	1

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3.	Quantitative and Qualitative Disclosure About Market Risk	24

Item 4.	Controls and Procedures	24

PART II – OTHER INFORMATION		25

Item 1.	Legal Proceedings	25

Item 1A.	Risk Factors	25

Item 2.	Recent Sales of Unregistered Securities; Use of Proceeds from Registered Securities	25

Item 3.	Defaults Upon Senior Securities	25

Item 4.	Mine Safety Disclosures	25

Item 5.	Other Information	25

Item 6.	Exhibits	25

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

INMUNE BIO, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

	March 31, 2021			December 31, 2020
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	45,340		$	21,967
Research and development tax credit receivable		2,190			1,686
Other tax receivable		154			113
Prepaid expenses		1,514			220
Prepaid expenses – related party		15			-

TOTAL CURRENT ASSETS		49,213			23,986

Operating lease – right of use asset – related party		147			156
Acquired in-process research and development intangible assets		16,514			16,514

TOTAL ASSETS	$	65,874		$	40,656

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES
Accounts payable and accrued liabilities	$	1,572		$	1,518
Accounts payable and accrued liabilities – related parties		10			34
Deferred liabilities		591			190
Operating lease, current liability – related party		23			34
TOTAL CURRENT LIABILITIES		2,196			1,776

Long-term operating lease liability – related party		116			126
TOTAL LIABILITIES		2,312			1,902

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding		-			-
Common stock, $0.001 par value, 200,000,000 shares authorized, 14,932,638 and 13,481,283 shares issued and outstanding, respectively		15			13
Additional paid-in capital		101,466			72,105
Accumulated other comprehensive income		12			11
Accumulated deficit		(37,931	)		(33,375	)
TOTAL STOCKHOLDERS’ EQUITY		63,562			38,754

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	65,874		$	40,656

The accompanying notes are an integral part of these unaudited consolidated financial statements.

INMUNE BIO, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

	Three months ended March 31,
	2021			2020

REVENUE	$	4		$	-

OPERATING EXPENSES
General and administrative		2,061			1,299
Research and development		2,491			793
Total operating expenses		4,552			2,092

LOSS FROM OPERATIONS		(4,548	)		(2,092	)

OTHER (EXPENSE) INCOME
Other (expense) income		(8	)		22
Total other (expense) income		(8	)		22

NET LOSS	$	(4,556	)	$	(2,070	)

Net loss per common share – basic and diluted	$	(0.32	)	$	(0.19	)

Weighted average number of common shares outstanding – basic and diluted		14,322,659			10,747,300

COMPREHENSIVE LOSS
Net loss	$	(4,556	)	$	(2,070	)
Other comprehensive income (loss) – foreign currency translation		1			(21	)
Total comprehensive loss	$	(4,555	)	$	(2,091	)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

INMUNE BIO, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(In thousands, except share amounts)

(Unaudited)

							Accumulated
					Additional		Other					Total
	Common Stock				Paid-In		Comprehensive		Accumulated			Stockholders’
	Shares		Amount		Capital		Income		Deficit			Equity
Balance as of December 31, 2020		13,481,283	$	13	$	72,105	$	11	$	(33,375	)	$	38,754
Issuance of common stock for cash		1,439,480		2		28,444		-		-			28,446
Exercise of warrants for cash		11,875		-		18		-		-			18
Stock-based compensation		-		-		899		-		-			899
Gain on foreign currency translation		-		-		-		1		-			1
Net loss		-		-		-		-		(4,556	)		(4,556	)
Balance as of March 31, 2021		14,932,638	$	15	$	101,466	$	12	$	(37,931	)	$	63,562

The accompanying notes are an integral part of these unaudited consolidated financial statements.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE THREE MONTHS ENDED MARCH 31, 2020

(In thousands, except share amounts)

(Unaudited)

											Accumulated
						Additional			Common		Other						Total
	Common Stock					Paid-In			Stock		Comprehensive			Accumulated			Stockholders’
	Shares			Amount		Capital			Issuable		Loss			Deficit			Equity
Balance as of December 31, 2019		10,770,948		$	11	$	44,834		$	50	$	(9	)	$	(21,276	)	$	23,610
Issuance of common stock and warrants for cash, net		196,000			-		1,003			-		-			-			1,003
Acquisition and retirement of common stock		(220,000	)		-		(1,012	)		-		-			-			(1,012	)
Capital contribution		-			-		216			-		-			-			216
Stock-based compensation		-			-		682			-		-			-			682
Loss on foreign currency translation		-			-		-			-		(21	)		-			(21	)
Net loss		-			-		-			-		-			(2,070	)		(2,070	)
Balance as of March 31, 2020		10,746,948		$	11	$	45,723		$	50	$	(30	)	$	(23,346	)	$	22,408

The accompanying notes are an integral part of these unaudited consolidated financial statements.

INMUNE BIO, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	For the Three Months Ended March 31,
	2021			2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(4,556	)	$	(2,070	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		899			682
Changes in operating assets and liabilities:
Research and development tax credit receivable		(504	)		(145	)
Other tax receivable		(41	)		6
Prepaid expenses		(1,294	)		(170	)
Prepaid expenses – related party		(15	)		26
Accounts payable and accrued liabilities		54			294
Accounts payable and accrued liabilities – related parties		(24	)		29
Deferred liabilities		401			300
Operating lease liability – related party		(12	)		13
Net cash used in operating activities		(5,092	)		(1,035	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of common stock		28,446			1,003
Net proceeds from the exercise of warrants		18			-
Purchase of common stock		-			(1,012	)
Net cash provided by (used in) financing activities		28,464			(9	)

Impact on cash from foreign currency translation		1			(21	)

NET INCREASE (DECREASE) IN CASH		23,373			(1,065	)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		21,967			6,996

CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	45,340		$	5,931

SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash paid for income taxes	$	-		$	-
Cash paid for interest expense	$	-		$	-

NONCASH INVESTING AND FINANCING ACTIVITIES:
Capital contribution	$	-		$	216

The accompanying notes are an integral part of these unaudited consolidated financial statements.

INMUNE BIO, INC.

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

INmune Bio, Inc. (the “Company” or “INmune Bio”) was organized in the State of Nevada on September 25, 2015, and is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient’s disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor), cancer (INB03), Alzheimer’s and treatment resistant depression (XPro595), and NASH (LIVNate). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.

NOTE 2 – LIQUIDITY

As of March 31, 2021, the Company had an accumulated deficit of approximately $37.9 million and experienced losses since its inception. Losses have principally occurred as a result of non-cash stock-based compensation expense and the substantial resources required for research and development of the Company’s products, which included the general and administrative expenses associated with its organization and product development as well as the lack of sources of revenues until such time as the Company’s products are commercialized.

To meet its current and future obligations the Company has taken the following steps to capitalize the business and achieve its business plan:

●

During March 2021, the Company entered into a sales agreement with BTIG, LLC (“BTIG”), as sales agent, to establish an At-The-Market (“ATM”) offering program of up to $45 million of common stock (the “2021 ATM”), subject to certain limitations on the amount of common stock that may be offered and sold by the Company set forth in the sales agreement. The Company is required to pay BTIG a commission of 3% of the gross proceeds from the sale of shares. There have been no sales of the Company’s common stock pursuant to the 2021 ATM.

●

During July 2020, the Company completed an underwritten public offering in which it sold 2,500,000 shares of common stock at a public offering price of $10.00 per share. Aggregate net proceeds from the underwritten public offering were approximately $23.1 million, net of $1.9 million in underwriting discounts and commissions and offering expenses.

●

During April 2020, the Company entered into a sales agreement with BTIG, as sales agent, to establish an ATM offering program to sell up to $10.0 million of the Company’s common stock (the “2020 ATM”). In August 2020, the sales agreement was amended whereby the aggregate offering was increased from $10.0 million to $30.0 million. From April 2020 through December 2020, the Company sold 178,600 shares of common stock at an average price of $5.45 per share for net proceeds of approximately $0.8 million. During the three months ended March 31, 2021, the Company sold in aggregate 1,439,480 shares on common stock at an average price of $20.17 per share for net proceeds of $28.4 million. As of March 31, 2021, sales of our common stock pursuant to the 2020 ATM have been completed.

Although it is difficult to predict the Company’s liquidity requirements, as of March 31, 2021, and based upon the Company’s current operating plan, the Company believes that it will have sufficient cash to meet its projected operating requirements for at least the next 12 months following the filing date of this Quarterly Report on Form 10-Q based on the balance of cash available as of March 31, 2021. The Company anticipates that it will continue to incur net losses for the foreseeable future as it continues the development of its clinical drug candidates and preclinical programs and incurs additional costs associated with being a public company.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of INmune Bio, Inc. and its subsidiaries. Intercompany transactions and balances have been eliminated.

In the opinion of management, the interim financial information includes all normal recurring adjustments necessary for a fair statement of the results for the interim periods. These unaudited consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 4, 2021.

Risks and Uncertainties

The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict. Also, economies worldwide have also been negatively impacted by the COVID-19 pandemic, however policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

In addition, the Company’s clinical trials have been affected by and may continue to be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment have and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients have not and others may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, the ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact the Company’s clinical trial operations.

The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s service providers, suppliers, contract research organizations (“CROs”) and the Company’s clinical trials, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations is uncertain.

Use of Estimates

Preparing financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management’s estimates and assumptions.

Cash and Cash Equivalents

The Company considers all short-term, highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. The Company maintains cash balances that may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation limits. The Company maintains its cash deposits with major financial institutions.

Research and Development Tax Incentive Receivable

The Company, through its wholly-owned subsidiary in Australia (“AUS”), participates in the Australian research and development tax incentive program, such that a percentage of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives are reflected as a reduction of research and development expense. The Australian research and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information at the time.

The Company, through its wholly-owned subsidiary in the United Kingdom (“UK”), participates in the research and development program provided by the United Kingdom tax relief program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United Kingdom government, and such incentives are reflected as a reduction of research and development expense. The United Kingdom research and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information at the time.

Intangible Assets

The Company capitalizes costs incurred in connection with in-process research and development purchased from others if the asset has alternative uses and such uses are not restricted under applicable license agreements; patent applications (principally legal fees), patent purchases, and trademarks related to its cell line as intangible assets. Acquired in-process research and development costs that do not have alternative uses are expensed as incurred. Amortization is initiated for acquired in-process research and development intangible assets when their useful lives have been determined. These acquired in-process research and development intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment.

Basic and Diluted Loss per Share

Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

At March 31, 2021 and 2020, the Company had potentially issuable shares as follows:

	March 31,
	2021		2020
Stock options		3,655,549		3,417,000
Warrants		2,126,047		1,658,199
Total		5,781,596		5,075,199

Revenue Recognition

The Company recognizes revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC Topic 606: (1) identify contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenues when (or as) the Company satisfies the performance obligations. The Company records the expenses related to revenue in research and development expense, in the periods such expenses were incurred.

The Company records deferred revenues when cash payments are received or due in advance of performance, including amounts which are refundable.

Stock-Based Compensation

The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock option awards at the date of grant, which requires the input of highly subjective assumptions, including expected volatility and expected life. Changes in these inputs and assumptions can materially affect the measure of estimated fair value of our share-based compensation. These assumptions are subjective and generally require significant analysis and judgment to develop. When estimating fair value, some of the assumptions will be based on, or determined from, external data and other assumptions may be derived from our historical experience with stock-based payment arrangements. The appropriate weight to place on historical experience is a matter of judgment, based on relevant facts and circumstances. The Company accounts for forfeitures of stock options as they occur.

Research and Development

Research and development (“R&D”) costs are expensed as incurred. Research and development credits are recorded by the Company as a reduction of research and development costs. Major components of research and development costs include cash compensation, stock-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf.

The Company recognizes grants as contra research and development expense in the consolidated statement of operations on a systematic basis over the periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate.

Income Taxes

The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Foreign Currency Translation

The Company’s financial statements are presented in the U.S. dollar (“$”), which is the Company’s reporting currency, while its functional currencies are the U.S. Dollar for its U.S. based operations, British Pound (“GBP”) for its United Kingdom-based operations and Australian Dollars (“AUD”) for its Australian-based operations. All assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income (loss).

Recently Adopted Accounting Pronouncements

There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on the Company´s consolidated financial position, operations or cash flows.

Subsequent Events

The Company evaluates events that have occurred after the balance sheet date of March 31, 2021, through the date which the financial statements are issued.

NOTE 4 – RESEARCH AND DEVELOPMENT ACTIVITY

According to UK tax law, the Company is allowed an R&D tax credit that reduces a company’s tax bill in the UK for expenses incurred in R&D subject to certain requirements. The Company’s UK subsidiary submits R&D tax credit requests annually for research and development expenses incurred. At March 31, 2021 and December 31, 2020, the Company recorded a research and development tax credit receivable in the amount of $1,104,000 and $833,000, respectively. During the three months ended March 31, 2021 and 2020, the Company received $0 of R&D tax credit reimbursements from the UK.

According to AUS tax law, the Company is allowed an R&D tax credit that reduces a company’s tax bill in AUS for expenses incurred in R&D subject to certain requirements. The Company’s Australian subsidiary submits R&D tax credit requests annually for research and development expenses incurred. At March 31, 2021 and December 31, 2020, the Company recorded a research and development tax credit receivable of $1,086,000 and $853,000, respectively, for R&D expenses incurred in Australia. During the three months ended March 31, 2021 and 2020, the Company received $0 R&D tax credit reimbursements from Australia.

Xencor, Inc. License Agreement

On October 3, 2017, the Company entered into a license agreement (“Xencor License Agreement”) with Xencor, Inc. (“Xencor”), which has discovered and developed a proprietary biological molecule that inhibits soluble tumor necrosis factor. Pursuant to the license agreement, Xencor granted the Company an exclusive worldwide, royalty-bearing license in licensed patent rights, licensed know-how and licensed materials (as defined in the license agreement) to make, develop, use, sell and import any pharmaceutical product that comprises, contains, or incorporates Xencor’s proprietary protein known as “XPro1595” that inhibits soluble tumor necrosis factor (or all modifications, formulations and variants of the licensed protein that specifically bind soluble tumor necrosis factor) alone or in combination with one or more active ingredients, in any dosage or formulation (“Licensed Products”). The Company believes the protein has numerous medical applications. Such additional alternative applications of the technology are available under the Xencor License Agreement. In connection with the Xencor License Agreement, the Company paid Xencor a one-time non-creditable and non-refundable fee of $100,000 and issued Xencor 1,585,000 shares of the Company’s common stock with a fair value of $12,221,000. In addition, the Company issued Xencor fully vested warrants with a fair value of $4,193,000 to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase. The aggregate purchase price for the full exercise of the option is $10,000,000 which purchase price shall be pro-rated for any partial exercise of the warrant. In August 2018, the Company entered into a First Amendment to Stock Issuance Agreement. Pursuant to the amendment, the purchase price for the additional shares may only be paid by cash. The warrants expire on October 3, 2023.

The Company recorded $16,514,000 for the acquisition of intangible assets for the in-process research and development as the fair value of the cash, stock and warrants on the date of the License Agreement acquisition in accordance with Accounting Standards Codification 730 – Research and Development. The Company has the license rights to pursue alternative applications of the technology as part of its future development plans.

The Company also agreed to pay Xencor a royalty on Net Sales of all Licensed Products in a given calendar year, which are payable on a country-by- country and licensed product by licensed product basis until the date that is the later of (a) the expiration of the last to expire valid claim covering such Licensed Product in such country or (b) ten years following the first sale to a third party of the licensed product in such country.

Under the Xencor License Agreement, the Company also agreed to pay Xencor a percentage of any sublicensing revenue that it receives.

INKmune License Agreement

On October 29, 2015, the Company entered into an exclusive license agreement (the “INKmune License Agreement”) with Immune Ventures, LLC (“Immune Ventures”). Pursuant to the INKmune License Agreement, the Company was granted exclusive worldwide rights to the patents, including rights to incorporate any improvements or additions to the patents that may be developed in the future. In consideration for the patent rights, the Company agreed to the following milestone payments (of which none have been met as of March 31, 2021):

(in thousands)

Each Phase I initiation	$	25
Each Phase II initiation	$	250
Each Phase III initiation	$	350
Each NDA/EMA filing	$	1,000
Each NDA/EMA awarded	$	9,000

In addition, the Company agreed to pay Immune Ventures a royalty of 1% of net sales during the life of each patent granted to the Company. RJ Tesi, the Company’s President and a member of our Board of Directors, David Moss, its Chief Financial Officer and Treasurer and Mark Lowdell, its Chief Scientific Officer, are the owners of Immune Ventures. As of March 31, 2021, no sales had occurred under this license.

The term of the agreement began on October 29, 2015 and, if not terminated sooner pursuant to the agreement, ends on a country-by-country basis on the date of the expiration of the last to expire patent rights where patent rights exists. Upon the termination of the agreement, we shall have a fully paid up, perpetual, royalty-free license without further obligation to Immune Ventures. The agreement can be terminated by Immune Ventures if, after 60 days from the Company’s receipt of notice that the Company has not made a payment under the agreement, and the Company still does not make this payment. On July 20, 2018, the parties amended the agreement under which the Company was required achieve milestones pursuant to the agreement. On October 30, 2020, the parties executed an additional amendment to the agreement under which the Company is required to achieve the following milestones:

Initiation of Phase 1 clinical or equivalent trials by October 29, 2021

Initiation of Phase II clinical trials or equivalent by October 29, 2023

Initiation of Phase III clinical trials or equivalent by October 29, 2025

Filing of NDA or equivalent by October 29, 2026 or equivalent

If the Company doesn’t achieve the above milestones, it is required to negotiate in good faith with Immune Ventures to determine how it can either remedy the failure or achieve an alternate development. If the Company fails to make any required efforts, or if the efforts do not remedy the situation within 60 days of written notice by Immune Ventures, then Immune Ventures may provide notice to terminate the license or convert it to a non-exclusive license.

University of Pittsburg License Agreement

On October 3, 2017, the Company entered into an Assignment and Assumption Agreement with Immune Ventures related to intellectual property licensed from the University of Pittsburgh. Pursuant to the Assignment and Assumption Agreement (“Assignment Agreement”), Immune Ventures assigned all of its rights, obligations and liabilities under an Exclusive License Agreement between the University of Pittsburgh – Of the Commonwealth System of Higher Education (“Licensor”) and Immune Ventures to INmune Bio (“Licensee”), (the “PITT Agreement”).

Consideration under the PITT Agreement includes: (i) annual maintenance fees, (ii) royalty payments based on the sale of products making use of the licensed technology, and (iii) milestone payments.

Annual maintenance fees under the PITT Agreement include the following:

(in thousands)

June 26 of each year 2021-2022	$	5
June 26 of each year 2023-2024	$	10
June 26 of each year 2025 until first commercial sale	$	25

Upon first commercial sale of a product making use of the licensed technology under the PITT Agreement, the Licensee is required to pay royalties equal to 2.5% of Net Sales each calendar quarter.

Moreover, under the PITT Agreement the Licensee is required to make milestone payments as follows:

(in thousands)

Each Phase I initiation

Each Phase III initiation

500

First commercial sale of product making use of licensed technology

1,250

The Company had no amounts owed pursuant to the PITT Agreement as of March 31, 2021.

The PITT Agreement expires upon the earlier of: (i) expiration of the last claim of the Patent Rights (as defined in the PITT Agreement) forming the subject matter of the PITT Agreement; or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037).

The Licensee may terminate the PITT Agreement upon 3 months prior written notice provided all payments under the license are current. The Licensor may terminate the PITT Agreement upon written notice if: (i) Licensee defaults as to performance of material obligations which have not been cured within 60 days after receiving written notice; or (ii) Licensee ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of debtors.

University College London License Agreement – MSC

On July 19, 2019, the Company entered into license agreement with UCL Business PLC (“UCLB”) with a ten (10) year term. Pursuant to the license agreement, the Company acquired an exclusive license (and a right to sub-license) to the technology and know-how relating to an isolation and commercial scale expansion methodology of GMP grade human umbilical cord mesenchymal stem/stromal cells (“MSC”).

In exchange for the license agreement, the Company paid UCLB an initial license fee of $10,000 and shall pay annual licensing fees of approximately $13,000 per year for the remaining term of the agreement. The Company will pay UCLB a royalty of 3-3.5%% of the net sales value (as defined in the agreement) of all licensed products sold or used by the Company. In the event the Company sub-licenses the technology and know-how, the Company will pay UCLB a royalty of twelve (12) percent of consideration (cash or non-cash) received by the Company in relation to the development or sub-licensing of any of the technology and know-how.

NOTE 5 – LEASE

In May 2019, the Company signed a sublease agreement with a related party for office space in La Jolla, California, which serves as the new headquarters of the Company. The lease has a 61-month term, which corresponds to the lease term of the lessor. The lessor is CTI Clinical Trial & Consulting Services (“CTI”). CTI is majority-owned by a member of the Company’s Board of Directors. The lessor may extend its lease for an additional 5 years, and, if it does, the Company may also extend its sublease for 5 years. The Company did not include the option to extend in the calculation of the lease liabilities as such extension is not reasonably certain to occur. Variable lease costs for the Company’s lease consists of operating expenses for the spaces. Below is a summary of the Company’s right-of-use assets and liabilities as of March 31, 2021:

(in thousands, except years and rate)

Right-of-use asset – related party	$	147

Operating lease, current liability – related party	$	23
Long-term operating lease liability – related party		116
Total lease liability	$	139

Weighted-average remaining lease term		3.2 years

Weighted-average discount rate		10.00	%

During the three months ended March 31, 2021, the Company recognized $13,000 in operating lease expense, which is included in general and administrative expenses in the Company’s consolidated statement of operations.

NOTE 6 – RELATED PARTY TRANSACTIONS

UCL

At March 31, 2021 and December 31, 2020, the Company owed UCL Consultants Limited (“UCL”) $10,000 and $34,000, respectively, in connection with medical research performed on behalf of the Company. At March 31, 2021 and December 31, 2020, the Company recorded prepaid expenses of $15,000 and $0, respectively, for medical research to be performed on behalf of the Company by UCL. During the three months ending March 31, 2021 and 2020, the Company paid UCL $88,000 and $0, respectively, for medical research performed on behalf of the Company. UCL is a wholly owned subsidiary of the University of London. The Company’s Chief Scientific and Manufacturing Officer is a professor at the University of London.

CTI

During the three months ending March 31, 2021 and 2020, the Company paid CTI $0 and $79,000, respectively, for medical research performed on behalf of the Company. During the three months ended March 31, 2020, the Company recorded a capital contribution of $216,000 for the forgiveness of certain accounts payable due to CTI. The Company had no amounts payable to CTI as of March 31, 2021 and December 31, 2020.

NOTE 7 – STOCKHOLDERS’ EQUITY

Lincoln Park

On May 15, 2019, the Company entered into both a securities purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Under the terms and subject to the conditions of the securities purchase agreement, the Company had the right to sell to Lincoln Park, and Lincoln Park was obligated to purchase, up to $20.0 million in shares of the Company’s common stock, subject to certain limitations, over the 24-month period that commenced on May 15, 2019. During the three months ended March 31, 2020, the Company issued 196,000 shares of its common stock to Lincoln Park for approximately $1.0 million of cash.

During April 2021, the Company terminated the securities purchase agreement with Lincoln Park.

Purchase and retirement of common stock

During January 2020, the Company purchased and cancelled 220,000 shares of its common stock from a shareholder in exchange for approximately $1.0 million of cash.

Common Stock – At the Market Offering

During the three months ended March 31, 2021, the Company sold 1,439,480 shares of its common stock for aggregate gross proceeds of approximately $29.0 million (net proceeds of approximately $28.4 million) under the 2020 ATM program. The Company paid BTIG commissions and fees of $582,000 in connection with the sale of these shares.

Stock options

During January 2021, the Company granted certain employees and directors options to purchase 198,549 shares of its common stock pursuant to the 2017 and 2019 Incentive Stock Plans. The stock options have a fair value of approximately $4.2 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 0.78% based on the applicable US Treasury bill rate (2) expected life of 6.0 - 6.25 years, (3) expected volatility of approximately 113% - 114% based on the trading history of similar companies, and (4) zero expected dividends.

The following table summarizes stock option activity during the three months ended March 31, 2021:

(in thousands, except share and per share amounts)	Number of Shares		Weighted- average Exercise Price		Weighted-average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at January 1, 2021		3,457,000	$	5.82		8.05	$	39,405
Options granted		198,549	$	24.82		-		-
Options exercised		-	$	-		-		-
Options cancelled		-	$	-		-		-
Outstanding at March 31, 2021		3,655,549	$	6.85		7.91	$	20,945
Exercisable at March 31, 2021		2,415,889	$	6.54		7.42	$	12,906

During the three months ended March 31, 2021 and 2020, the Company recognized stock-based compensation expense of approximately $0.9 million and $0.7 million, respectively, related to the vesting of stock options. As of March 31, 2021, there was approximately $7.3 million of total unrecognized compensation cost related to non-vested stock options which is expected to be recognized over a weighted-average period of 2.72 years.

Warrants

In connection with the Company’s initial public offering in February 2019, the Company issued warrants to the placement agents to purchase the Company’s common stock at an exercise price of $9.60 per common share, which warrants are exercisable until December 19, 2023. At March 31, 2021, 34,835 of these warrants are outstanding and the intrinsic value is $79,000.

In October 2017, in connection with the Xencor License Agreement, the Company issued fully vested warrants to purchase an additional number of shares of common stock equal to 10% of the fully diluted Company shares immediately following such purchase. See Note 4. These warrants had an intrinsic value of approximately $14.6 million as of March 31, 2021.

On June 30, 2017, the Company issued fully vested warrants to purchase 31,667 shares of the Company’s common stock to a third party in conjunction with the common stock sold for cash. The warrants have a $1.50 exercise price and expire on June 30, 2022. During the three months ended March 31, 2021, 11,875 of these warrants were exercised for cash proceeds of $18,000. At March 31, 2021, 19,792 of these warrants are outstanding, with an intrinsic value of $205,000.

Stock-based Compensation by Class of Expense

The following summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three months ended March 31, 2021 and 2020 respectively:

(in thousands)	Three Months Ended March 31, 2021		Three Months Ended March 31, 2020
Research and development	$	186	$	139
General and administrative		713		543
Total	$	899	$	682

Shareholder Rights Agreement

On December 30, 2020, the Board of Directors (the “Board”) of the Company approved and adopted a Rights Agreement, dated as of December 30, 2020, by and between the Company and VStock Transfer, LLC, as rights agent, pursuant to which the Board declared a dividend of one preferred share purchase right (each, a “Right”) for each outstanding share of the Company’s common stock held by stockholders as of the close of business on January 11, 2021. When exercisable, each right initially would represent the right to purchase from the Company one one-thousandth of a share of a newly designated series of preferred stock, Series A Junior Participating Preferred Stock, par value $0.001 per share, of the Company, at an exercise price of $300.00 per one one-thousandth of a Series A Junior Participating Preferred Share, subject to adjustment. Subject to various exceptions, the Rights become exercisable in the event any person (excluding certain exempted or grandfathered persons) becomes the beneficial owner of twenty percent or more of the Company’s common stock without the approval of the Board. The Rights are scheduled to expire on December 30, 2021.

NOTE 8 – COLLABORATIVE AGREEMENTS

During 2020, the Company was awarded a $0.5 million grant from the Amyotrophic Lateral Sclerosis (“ALS”) Association to fund a study of the efficacy of XPro1595 to reverse ALS in vitro and to fund a study of the efficacy of XPro1595 to protect against ALS model phenotypes in vivo. During the three months ended March 31, 2021 and 2020, the Company received $0.1 million and $0.3 million, respectively, of cash proceeds pursuant to this grant which the Company recorded as deferred liabilities. The Company offsets costs incurred related to this research against the grants. As of March 31, 2021 and December 31, 2020, the Company recorded approximately $0.2 million and $0.1 million, respectively, as deferred liabilities in the consolidated balance sheet related to the ALS grant.

During September 2020, the Company was awarded a grant of up to $2.9 million from the National Institutes of Health (“NIH”). The grant will support a Phase 2 study of XPro1595 in patients with treatment resistant depression. As of March 31, 2021, the Company has not received any proceeds pursuant to this grant.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. These factors include but are not limited to economic conditions generally and in the industries in which we may participate; competition within our chosen industry, including competition from much larger competitors; technological advances and failure to successfully develop business relationships.

Description of Business

Overview

We are a clinical-stage immunotherapy company focused on developing drugs that may reprogram the patient’s innate immune system to treat disease. We believe this may be done by targeting cells of the innate immune system that cause acute and chronic inflammation and are involved in the immune dysfunction associated with chronic diseases such as cancer, neurodegenerative, metabolic and infectious diseases. The Company has two therapeutic platforms – dominant-negative TNF platform (“DN-TNF”) and the Natural Killer (“NK”) platform. The DN-TNF platform neutralizes soluble TNF (“sTNF”) without affecting trans-membrane TNF (“tmTNF”) or the receptors TNFR1 and TNFR2. This unique biologic mechanism differentiates the DN-TNF drugs from currently approved non-selective TNF inhibitors that inhibit the function of both sTNF and tmTNF. Protecting the function of tmTNF while neutralizing the function of sTNF is a potent anti-inflammatory drug that does not cause immunosuppression or demyelination. Currently approved non-selective TNF inhibitors are approved to treat autoimmune disease, however they are contraindicated in patients with infection, cancer and neurologic diseases because they increase the risk of infection, cancer and demyelinating neurologic diseases, respectively, because of off-target effects on inhibiting tmTNF. The NK platform targets the dysfunctional natural killer cells (“NK cells”) in patients with cancer. NK cells are part of the normal immunologic response to cancer with important roles in immunosurveillance to prevent cancer and in preventing relapse by clearing residual disease. Residual disease is the cancer left behind, often undetected, that can grow and cause relapse. The NK cells of cancer patients have the ability to kill cancer cells but are not effective because cancer cells mutate to evade NK cell immune surveillance. INKmune provides the missing signals needed to prime NK cells to overcome the immune evasion mutation to allow NK cells to kill the cancer cell. We believe INKmune is best used to eliminate residual disease after the patient has completed other cancer therapies. Both the DN-TNF platform and the INKmune platform can be used to treat multiple diseases. The DN-TNF platform will be used as an immunotherapy for the treatment of cancer, neurodegenerative, metabolic and infectious diseases. INKmune is being developed to treat NK sensitive hematologic malignancies and solid tumors.

We believe our DN-TNF platform can be used to reverse resistance in immunotherapy, to target glial activation to prevent progression of Alzheimer’s disease (“AD”), to target neuroinflammation in treatment resistant depression (“TRD”), to target intestinal leak and inflammation to treat non-alcoholic steatohepatitis (“NASH”) and to treat complications of the cytokine storm associated with COVID-19 infection. The drug is named differently for each indication; INB03, XPro1595, LIVNate and Quellor, respectively, but it is the same drug product. In each case, we believe neutralizing sTNF is a cornerstone to the treatment of each of these diseases. As an immunotherapy for cancer, we are using INB03 to neutralize sTNF produced by HER2+ trastuzumab resistant breast cancers to reverse resistance to therapy. sTNF causes an up-regulation of MUC4 expression that causes steric hindrance of trastuzumab binding to the HER2/Neu receptor on HER2+ breast cancer cells. Without binding, trastuzumab is not effective. In addition, INB03 changes the immunobiology of the tumor microenvironment by decreasing the number of immunosuppressive myeloid cells, both myeloid derived suppressor cells and tumor active macrophages, and increasing the number of cytotoxic lymphocytes in the TME. The Company has completed an open label dose escalation trial in cancer patients with metastatic solid tumors that have failed multiple lines of therapy. The trial informs the design of the Phase II trial by demonstrating that INB03 was safe and well tolerated, defined the dose of INB03 to carry into Phase II trials, and demonstrated a pharmacodynamic end-point. A Phase II trial is planned in women with advanced HER2+ breast cancer with metastasis.

Likewise, we believe the DN-TNF platform can be used to treat selected neurodegenerative diseases. XPro1595 is being used to treat patients with Alzheimer’s disease in a Phase I trial partially funded by a Part-the-Clouds Award from the Alzheimer’s Association. XPro1595 targets activated microglia and astrocytes of the brain that produce sTNF that promotes nerve cell loss and synaptic dysfunction, key elements in the development of dementia. In animal models, elimination of sTNF prevents nerve cell dysfunction and reverses synaptic pruning. The Phase I trial in patients with biomarkers of inflammation with AD is enrolling patients. The open label, dose escalation trial is designed to demonstrate that XPro1595 decreases neuroinflammation in patients with AD. This end-points of the trial are measures of neuroinflammation and neurodegeneration in blood and cerebral spinal fluid, measures of neuroinflammation by MRI by measuring white matter free water and breath by measuring volatile organic compounds in exhaled breath and by monitoring neuropsychiatric symptoms known to be associated with neuroinflammation including depression, apathy, aggression, hallucinations and sleep disorders.

In addition, we believe the DN-TNF platform can be used to treat selected metabolic diseases. LIVNate is being developed to treat NASH. NASH is a pleiotropic disease caused by a complex mix of metabolic, inflammatory and fibrotic pathophysiology. We believe targeting inflammation caused by intestinal leak, mesenteric and peripheral fat will prevent lipotoxicity, hepatic stellate cell activation and hepatocyte death that causes fibrosis and liver dysfunction associated with advanced disease. sTNF is elevated in obesity and is believed to cause intestinal leak. Intestinal leak combined with cytokines coming from mesenteric fat may dramatically increase the concentration of inflammatory cytokines in portal blood destined for the liver. The cytokine load contributes to the development of non-alcoholic fatty liver disease (“NAFLD”) and progression to NASH. LIVNate, by neutralizing sTNF improves insulin sensitivity, decreases the inflammation in peripheral and mesenteric fat and may also seal the intestinal leak. This combination prevents development of NAFLD or NASH in animal models. The Company is planning a Phase II open label randomized study using non-invasive measures to enroll patients with NASH in a study using a fixed dose of LIVNate delivered as a once a week sub-cutaneous injection.

We also believe the DN-TNF platform may be used to treat the complications associated with the cytokine storm caused by coronavirus disease 2019 (“COVID-19”). Three inflammatory cytokines make up the cytokine storm associated with COVID19 infection – sTNF, IL-6 and IL-1β. Targeting sTNF with Quellor may have advantages because IL-6 and IL-1 expression occur after sTNF expression; sTNF promotes endothelial activation causing expression of proteins that promote trafficking of immune cells from the blood vessel to the tissue and expression of Tissue Factor that stimulates the coagulopathy that is a prominent pathology of COVID-19 infection. The Company plans a Phase II trial in patients with symptomatic COVID-19 infection and hypoxia. The goal of the study is to prevent the catastrophic complications of advanced COVID-19 infection including one or more of the need for mechanical ventilation, new onset of cardiovascular, neurologic or thromboembolic disease, admission to an intensive care unit or death. The randomized trial will treat patients requiring hospitalization because of their disease.

Effective therapy for treatment resistant depression (TRD) is a large unmet need. Twenty percent of patients with a Major Depressive Disorder have TRD. Once third of TRD patients have peripheral biomarkers to inflammation (elevated CRP). This is a large patient population. The role of TNF and anti-TNF therapeutics was explored in a small open label clinical trial by Prof. Andrew Miller, MD of Emory University demonstrated the patients have elevated TNF levels and treatment with infliximab treated their depression (Miller, 2011). The Company received a $2.9M USD award from the National Institute of Mental Health (NIMH) to treat TRD with XPro1595. The blinded, randomized Phase II trial will use a biomarkers of peripheral inflammation to select patients with TRD for enrollment. Patients will be treated for 6 weeks. Primary end-points include both clinical and neuroimaging measures. The final trial design has is ongoing and discussions with the FDA are not complete. The Company anticipates receiving authorization to initiate the clinical trial in the second half of 2021.

We believe that INKmune improves the ability of the patient’s own NK cells to attack their tumor. INKmune interacts with the patient’s NK cells to convert them from inert resting NK cells that ignores the cancer into primed NK cells that kill the cancer cell. INKmune is a replication incompetent proprietary cell line we have named INB16 that is given to the patient after determining that i) the patient has adequate NK cells in their circulation and ii) those NK cells are functional when exposed to INKmune in vitro. INKmune is designed to be given to patients after their immune system has recovered after cytotoxic chemotherapy to target the residual disease the remains after treatment with cytotoxic therapy. INKmune can be used to treat numerous hematologic malignancies and solid tumors including leukemia, multiple myeloma, lymphoma, lung, ovary, breast, renal and prostate cancer. The Company plans Phase I trials using INKmune to treat patients with high risk MDS, a form of leukemia and women with relapsed refractory ovarian.

Since our inception in 2015, we have devoted substantially all of our resources to the discovery and development of our product candidates, including clinical trials and preclinical studies as well as general and administrative support for these operations. To date, we have generated no significant revenue. We have incurred net losses in each year since our inception and, as of March 31, 2021, we had an accumulated deficit of approximately $37.9 million. Our net losses were $4,556,000 and $2,070,000 for the three months ended March 31, 2021 and 2020, respectively. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations, including stock-based compensation.

We classify our operating expenses into two categories: research and development; and general and administrative expenses. Personnel costs including salaries, benefits and stock-based compensation expense comprise a significant component of our research and development and general and administrative expense categories.

We qualify as an “emerging growth company” under the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include:

	●	only two years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;

	●	reduced disclosure about our executive compensation arrangements;

	●	no non-binding advisory votes on executive compensation or golden parachute arrangements;

	●	exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting; and

	●	delaying the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies.

We have elected to take advantage of the above-referenced exemptions and we may take advantage of these exemptions for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1.07 billion in annual revenues, we have more than $700 million in market value of our stock held by non-affiliates, or we issue more than $1 billion of non-convertible debt over a three-year period. We may choose to take advantage of some but not all of these reduced burdens.

Research and Development

Research and development expense consists of expenses incurred while performing research and development activities to discover and develop our product candidates. This includes conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for product candidates. We recognize research and development expenses as they are incurred. Our research and development expense primarily consist of:

●

clinical trial and regulatory-related costs;

	●	expenses incurred under agreements with investigative sites and consultants that conduct our clinical trials;

	●	manufacturing and testing costs and related supplies and materials; and

	●	employee-related expenses, including salaries, benefits, travel and stock-based compensation.

We typically use our employee, consultant and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program, but we do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates or development programs.

We participate, through our wholly-owned subsidiary in Australia, in the Australian research and development tax incentive program, such that a percentage of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives are reflected as a reduction of research and development expense. The Australian research and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. In the future, the Company may elect to cease to perform research and development in Australia at which point the Company may not participate the Australian research and development tax incentive program.

We participate, through our wholly-owned subsidiary in the United Kingdom, in the research and development program provided by the United Kingdom tax relief program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United Kingdom government, and such incentives are reflected as a reduction of research and development expense. The United Kingdom research and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. In the future, the Company may elect to cease to perform research and development in the United Kingdom at which point the Company may not participate in the United Kingdom tax relief program.

Substantially all of our research and development expenses to date have been incurred in connection with our current and future product candidates. We expect our research and development expenses to increase significantly for the foreseeable future as we advance an increased number of our product candidates through clinical development, including the conduct of our planned clinical trials and manufacturing drug to be used in those clinical trials. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. The successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates.

The costs of clinical trials may vary significantly over the life of a project owing to, but not limited to, the following:

	●	per patient trial costs;

	●	the number of sites included in the clinical trials;

	●	the countries in which the clinical trials are conducted;

	●	the length of time required to enroll eligible patients;

	●	the number of patients that participate in the clinical trials;

	●	the number of doses that patients receive;

	●	the cost of comparative agents used in clinical trials;

	●	the drop-out or discontinuation rates of patients;

	●	potential additional safety monitoring or other studies requested by regulatory agencies;

	●	the duration of patient follow-up;

	●	the efficacy and safety profile of the product candidate; and

	●	the cost of manufacturing, finishing, labelling and storage drug used in the clinical trial.

We do not expect any of our product candidates to be commercially available for at least the next several years, if ever. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, which may fluctuate significantly from quarter-to-quarter and year-to-year. We anticipate that our expenses will increase substantially as we:

	●	continue research and development, including preclinical and clinical development of our existing product candidates;

	●	potentially seek regulatory approval for our product candidates;

	●	seek to discover and develop additional product candidates;

	●	establish a commercialization infrastructure and scale up our manufacturing and distribution capabilities to commercialize any of our product candidates for which we may obtain regulatory approval;

	●	seek to comply with regulatory standards and laws;

	●	maintain, leverage and expand our intellectual property portfolio;

	●	hire clinical, manufacturing, scientific and other personnel to support our product candidates development and future commercialization efforts;

	●	add operational, financial and management information systems and personnel; and

	●	incur additional legal, accounting and other expenses in operating as a public company.

General and Administrative Expenses

General and administrative expenses consist principally of payroll and personnel expenses, including stock-based compensation; professional fees for legal, consulting, accounting and tax services; overhead, including rent and utilities; and other general operating expenses not otherwise classified as research and development expenses.

Other income (expense)

Other income primarily consists of interest income on money market accounts and foreign currency exchange gains and losses.

Results of Operations

Comparison of the Three Months Ended March 31, 2021 and 2020

The following table summarizes our results of operations for the periods indicated:

	Three Months Ended March 31,
(in thousands)	2021			2020			Change
Revenues	$	4			-			4
Operating expenses:
Research and development	$	2,491		$	793		$	1,698
General and administrative		2,061			1,299			762
Total operating expenses		4,552			2,092			2,460
Loss from operations		(4,548	)		(2,092	)		(2,456	)
Other (expense) income		(8	)		22			(30	)
Net loss	$	(4,556	)	$	(2,070	)	$	(2,486	)

Revenues

During the three months ended March 31, 2021, the Company sold MSC’s to one third-party and recognized $4,000 of revenues. There were no revenues during the three months ended March 31, 2020.

General and Administrative

General and administrative expenses were approximately $2.1 million during the three months ended March 31, 2021, compared to approximately $1.3 million during the three months ended March 31, 2020. The increase in general and administrative expenses is largely due to higher professional fees ($0.5 million higher during the three months ended March 31, 2021) and higher stock-based compensation ($0.2 million higher during the three months ended March 31, 2021).

Research and Development

Research and development expenses were approximately $2.5 million during the three months ended March 31, 2021, compared to approximately $0.8 million during the three months ended March 31, 2020. The increase in research and development expenses during the three months ending March 31, 2021 compared to the three months ending March 31, 2020 is largely due to additional amounts incurred related to manufacturing additional drugs and amounts incurred in connection with the Company’s COVID-19 clinical trial.

Other Income (Expense)

The Company’s other income (expense) is mainly interest earned from money market accounts and foreign exchange gains and losses.

Liquidity and Capital Resources

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations and otherwise operate on an ongoing basis.

We incurred a net loss of $4,556,000 and $2,070,000 for the three months ended March 31, 2021 and 2020, respectively. Net cash used in operating activities was $5,092,000 and $1,035,000 for the three months ended March 31, 2021 and 2020, respectively. Since inception, we have funded our operations primarily with proceeds from the sales of our common stock. As of March 31, 2021, we had cash and cash equivalents of approximately $45.3 million. We anticipate that operating losses and net cash used in operating activities will increase over the next few years as we advance our products under development.

Our primary uses of capital are, and we expect will continue to be, third-party clinical and preclinical research and development services, compensation and related expenses, professional fees, patent and other regulatory expenses and general overhead costs. We believe our use of CROs provides us with flexibility in managing our spending.

The Company incurs the majority of its research and development expenses in Australia and the United Kingdom. Fluctuations in the rate of exchange between the United States dollar and the pound sterling as well as the Australian dollar could adversely affect our financial results, including our expenses as well as assets and liabilities. We currently do not hedge foreign currencies but will continue to assess whether that strategy is appropriate. As of March 31, 2021, the cash balance held by our foreign subsidiaries with currencies other than the United States dollar was approximately $0.3 million. We do not have any material financial exposure to one customer or one country that would significantly hinder our liquidity.

As a publicly traded company, we incur significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act of 2002, as well as rules adopted by the SEC and The Nasdaq Stock Market, require public companies to implement specified corporate governance practices that were inapplicable to us as a private company. We expect these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly.

As of March 31, 2021, the Company had an accumulated deficit of $37,931,000 and working capital of $47,017,000. Losses have principally occurred as a result of stock-based compensation expense as well as the substantial resources required for research and development of the Company’s products which included the general and administrative expenses associated with its organization and product development, as well as the lack of sources of revenues until such time as the Company’s products are commercialized. As of March 31, 2021, we had cash and cash equivalents of approximately $45.3 million. We believe our cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months following the filing date of this Quarterly Report on Form 10-Q based on the balance of cash available as of March 31, 2021.

ATM Sales Agreement

During the three months ended March 31, 2021, we issued and sold 1,439,480 shares of common stock at an average price of $20.17 per share under the 2020 ATM program. The aggregate net proceeds were approximately $28.4 million after BTIG’s commission and other offering expenses.

During March 2021, the Company entered into the 2021 ATM program with BTIG, as sales agent, to establish an ATM offering program of up to $45 million of common stock. There have been no sales of the Company’s common stock pursuant to 2021 ATM.

The Lincoln Park Transaction

On May 15, 2019, the Company and Lincoln Park entered a purchase agreement (the “Purchase Agreement”) pursuant to which the Company had the right to sell to Lincoln Park up to $20.0 million in shares of the Company’s common stock, subject to certain limitations and conditions set forth in the Purchase Agreement. During the three months ended March 31, 2020, the Company issued 196,000 shares of the Company’s common stock to Lincoln Park for gross proceeds of $1,003,000. During April 2021, the Company terminated the Purchase Agreement.

Grants

During the three months ended March 31, 2020, the Company was awarded a $500,000 grant from the Amyotrophic Lateral Sclerosis Association (“ALS”) to fund a study of the efficacy of XPro1595 to reverse ALS in vitro and to fund a study of the efficacy of XPro1595 to protect against ALS model phenotypes in vivo. During the three months ended March 31, 2021 and 2020, the Company received $100,000 and $300,000, respectively, of cash proceeds pursuant to this grant which the Company recorded within deferred liabilities. The Company records costs incurred related to the ALS study as a reduction of deferred liabilities. As of March 31, 2021 and December 31, 2020, the Company recorded $222,000 and $122,000, respectively, as deferred liabilities in the consolidated balance sheets related to the ALS grant.

Cash Flows

The following table summarizes our cash flows for the periods indicated:

	Three Months Ended March 31,
(in thousands)	2021			2020
Net cash and cash equivalents (used in) provided by:
Operating activities	$	(5,092	)	$	(1,035	)
Financing activities		28,464			(9	)
Change in cash and cash equivalents		23,372			(1,044	)
Impact on cash from foreign currency translation		1			(21	)
Cash and cash equivalents, beginning of period		21,967			6,996
Cash and cash equivalents, end of period	$	45,340		$	5,931

Operating Activities

Our cash used in operating activities was primarily driven by our net loss.

Operating activities used approximately $5.1 million of cash during the three months ended March 31, 2021, resulting from our loss of $4.6 million and changes in our net operating assets and liabilities of $1.4 million, partially offset by non-cash stock-based compensation of $0.9 million. The change in our net operating assets and liabilities was mainly due to an increase in prepaid expenses of approximately $1.3 million, and an increase in research and development tax credit receivable of $0.5 million, partially offset by an increase in deferred liabilities of approximately $0.4 million.

Operating activities used approximately $1.0 million of cash for the three months ended March 31, 2020, primarily resulting from our net loss of approximately $2.1 million, a net cash inflow of approximately $0.4 million for changes in our net operating assets and liabilities, and non-cash stock-based compensation charges of approximately $0.7 million. The change in our net operating assets and liabilities was primarily driven by an increase in accounts payable and accrued liabilities of approximately $0.3 million and an increase in deferred grant of $0.3 million, partially offset by an increase in prepaid expenses of approximately $0.2 million, and an increase in research and development tax credit receivable of approximately $0.1 million.

Financing Activities

During the three months ended March 31, 2021, the Company sold 1,439,480 shares of its common stock under its 2020 ATM program for net proceeds of approximately $28.4 million.

During the three months ended March 31, 2020, the Company purchased 220,000 shares from an investor for approximately $1.0 million. In addition, the Company sold 196,000 shares of its common stock to Lincoln Park for cash proceeds of approximately $1.0 million.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations is based upon our unaudited consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. Actual results may differ from these estimates. Our critical accounting policies and estimates are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and there have been no material changes during the three months ended March 31, 2021.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) at the end of the period covered by this quarterly report.

Based on this evaluation, we concluded that, as of such date, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

We recognize that any controls system, no matter how well designed and operated, can provide only reasonable assurance of achieving its objectives, and our management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the period covered by this quarterly report that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not currently a party to any pending legal proceedings that we believe will have a material adverse effect on our business or financial conditions. We may, however, be subject to various claims and legal actions arising in the ordinary course of business from time to time.

Item 1A. Risk Factors

Not required for smaller reporting companies.

Item 2. Recent Sales of Unregistered Securities; Use of Proceeds from Registered Securities

None.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits

No.		Description
31.1		Rule 13a-14(a)/ 15d-14(a) Certification of Chief Executive Officer*

31.2		Rule 13a-14(a)/ 15d-14(a) Certification of Chief Financial Officer*

32.1		Section 1350 Certification of Chief Executive Officer**

32.2		Section 1350 Certification of Chief Financial Officer**

101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema
101.CAL		XBRL Taxonomy Extension Calculation Linkbase
101.DEF		XBRL Taxonomy Extension Definition Linkbase
101.LAB		XBRL Taxonomy Extension Label Linkbase
101.PRE		XBRL Taxonomy Extension Presentation Linkbase

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	INmune Bio Inc.

Date: May 5, 2021	By:	/s/ Raymond J. Tesi
		Raymond J. Tesi
		Chief Executive Officer (Principal Executive Officer)

Date: May 5, 2021

By:

/s/ David J. Moss

David J. Moss

Chief Financial Officer, Treasurer, Secretary

(Principal Financial and Accounting Officer)

EX-31.1 2 f10q0321_ex31-1inmunebio.htm CERTIFICATION

EXHIBIT 31.1

Certifications

I, Raymond J. Tesi, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of INmune Bio Inc.

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2021

/s/ Raymond J. Tesi

Raymond J. Tesi

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 f10q0321_ex31-2inmunebio.htm CERTIFICATION

EXHIBIT 31.2

Certifications

I, David J. Moss, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of INmune Bio Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2021


/s/ David J. Moss
David J. Moss
Chief Financial Officer (Principal Financial Officer)

EX-32.1 4 f10q0321_ex32-1inmunebio.htm CERTIFICATION

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of INmune Bio Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Raymond J. Tesi, Chief Executive Officer of the Company, certify to my knowledge and in my capacity, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 5, 2021


/s/ Raymond J. Tesi
Raymond J. Tesi
Chief Executive Officer (Principal Executive Officer)

EX-32.2 5 f10q0321_ex32-2inmunebio.htm CERTIFICATION

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of INmune Bio Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David J. Moss, Chief Financial Officer of the Company, certify to my knowledge and in my capacity, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 5, 2021


/s/ David J. Moss
David J. Moss
Chief Financial Officer (Principal Financial Officer)

EX-101.INS 6 inmb-20210331.xml XBRL INSTANCE FILE 0001711754 2021-01-01 2021-03-31 0001711754 2021-05-05 0001711754 2021-03-31 0001711754 2020-12-31 0001711754 2020-01-01 2020-03-31 0001711754 us-gaap:CommonStockMember 2020-12-31 0001711754 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001711754 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001711754 us-gaap:RetainedEarningsMember 2020-12-31 0001711754 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001711754 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001711754 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001711754 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001711754 us-gaap:CommonStockMember 2021-03-31 0001711754 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001711754 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001711754 us-gaap:RetainedEarningsMember 2021-03-31 0001711754 us-gaap:CommonStockMember 2019-12-31 0001711754 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001711754 inmb:CommonStockIssuableMember 2019-12-31 0001711754 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001711754 us-gaap:RetainedEarningsMember 2019-12-31 0001711754 2019-12-31 0001711754 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001711754 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001711754 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001711754 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001711754 inmb:CommonStockIssuableMember 2020-01-01 2020-03-31 0001711754 us-gaap:CommonStockMember 2020-03-31 0001711754 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001711754 inmb:CommonStockIssuableMember 2020-03-31 0001711754 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001711754 us-gaap:RetainedEarningsMember 2020-03-31 0001711754 2020-03-31 0001711754 inmb:InitialPublicOfferingMember 2020-07-01 2020-07-31 0001711754 inmb:InitialPublicOfferingMember 2020-07-31 0001711754 inmb:ATMOfferingProgramMember 2020-04-01 2020-04-30 0001711754 srt:MinimumMember inmb:SalesAgreementMember 2020-04-01 2020-04-30 0001711754 srt:MaximumMember inmb:SalesAgreementMember 2020-04-01 2020-04-30 0001711754 inmb:SalesAgreementMember 2020-04-01 2020-12-31 0001711754 inmb:SalesAgreementMember 2020-12-31 0001711754 inmb:SalesAgreementMember 2021-01-01 2021-03-31 0001711754 inmb:SalesAgreementMember 2021-03-31 0001711754 us-gaap:EmployeeStockMember 2021-01-01 2021-03-31 0001711754 us-gaap:EmployeeStockMember 2020-01-01 2020-03-31 0001711754 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001711754 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001711754 pf0:GB us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001711754 pf0:GB us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001711754 pf0:AU us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001711754 pf0:AU us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001711754 inmb:XencorInc.LicenseAgreementMember 2017-09-04 2017-10-03 0001711754 inmb:XencorInc.LicenseAgreementMember 2017-10-03 0001711754 inmb:XencorInc.LicenseAgreementMember 2021-01-01 2021-03-31 0001711754 inmb:InkmuneLicenseAgreementMember 2021-03-31 0001711754 inmb:UniversityOfPittsburgLicenseAgreementMember 2021-01-01 2021-03-31 0001711754 inmb:ImmuneVenturesToInmuneBioMember 2021-01-01 2021-03-31 0001711754 inmb:MilestonePaymentPhaseOneInitiationMember us-gaap:PatentsMember inmb:ImmuneVenturesLlcMember inmb:InkmuneLicenseAgreementMember 2021-01-01 2021-03-31 0001711754 inmb:MilestonePaymentPhaseTwoInitiationMember us-gaap:PatentsMember inmb:ImmuneVenturesLlcMember inmb:InkmuneLicenseAgreementMember 2021-01-01 2021-03-31 0001711754 inmb:MilestonePaymentPhaseThreeInitiationMember us-gaap:PatentsMember inmb:ImmuneVenturesLlcMember inmb:InkmuneLicenseAgreementMember 2021-01-01 2021-03-31 0001711754 inmb:MilestonePaymentNdaEmaFilingMember us-gaap:PatentsMember inmb:ImmuneVenturesLlcMember inmb:InkmuneLicenseAgreementMember 2021-01-01 2021-03-31 0001711754 inmb:MilestonePaymentNdaEmaAwardedMember us-gaap:PatentsMember inmb:ImmuneVenturesLlcMember inmb:InkmuneLicenseAgreementMember 2021-01-01 2021-03-31 0001711754 inmb:FirstCommercialSaleOfEachYearTwoZeroEighteenToTwoZeroTwentyTwoMember inmb:AnnualMaintenanceFeesMember inmb:UniversityOfPittsburgLicenseAgreementMember 2021-03-31 0001711754 inmb:SecondCommercialSaleOfEachYearTwoZeroTwentyThreeToTwoZeroTwentyFourMember inmb:AnnualMaintenanceFeesMember inmb:UniversityOfPittsburgLicenseAgreementMember 2021-03-31 0001711754 inmb:AnnuallyCommercialSaleThereafterMember inmb:AnnualMaintenanceFeesMember inmb:UniversityOfPittsburgLicenseAgreementMember 2021-03-31 0001711754 inmb:MilestonePaymentPhaseOneInitiationMember inmb:ImmuneVenturesToInmuneBioMember 2021-01-01 2021-03-31 0001711754 inmb:EachPhaseIIIInitiationMember inmb:ImmuneVenturesToInmuneBioMember 2021-01-01 2021-03-31 0001711754 us-gaap:TechnologyBasedIntangibleAssetsMember inmb:ImmuneVenturesToInmuneBioMember 2021-01-01 2021-03-31 0001711754 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001711754 inmb:UclConsultantsLimitedMember 2021-03-31 0001711754 inmb:UclConsultantsLimitedMember 2020-12-31 0001711754 inmb:UclConsultantsLimitedMember 2021-01-01 2021-03-31 0001711754 inmb:UclConsultantsLimitedMember 2020-01-01 2020-03-31 0001711754 inmb:ClinicalTrialAndConsultingServicesMember 2021-01-01 2021-03-31 0001711754 inmb:ClinicalTrialAndConsultingServicesMember 2020-01-01 2020-03-31 0001711754 inmb:LincolnParkMember 2019-05-01 2019-05-15 0001711754 inmb:LincolnParkMember us-gaap:CommonStockMember 2019-05-01 2019-05-15 0001711754 inmb:LincolnParkMember us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001711754 us-gaap:CommonStockMember 2020-01-01 2020-01-20 0001711754 inmb:ATMProgramMember 2021-01-01 2021-03-31 0001711754 inmb:BTIGsCommissionMember 2021-01-01 2021-03-31 0001711754 inmb:EmployeesAndDirectorsMember 2021-01-31 0001711754 2021-01-01 2021-01-31 0001711754 srt:MinimumMember 2021-01-01 2021-01-31 0001711754 srt:MaximumMember 2021-01-01 2021-01-31 0001711754 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001711754 us-gaap:WarrantMember 2019-02-28 0001711754 inmb:XencorLicenseAgreementMember 2021-03-31 0001711754 inmb:XencorLicenseAgreementMember 2021-01-01 2021-03-31 0001711754 2017-10-01 2017-10-31 0001711754 us-gaap:WarrantMember 2017-06-01 2017-06-30 0001711754 us-gaap:WarrantMember 2020-07-31 0001711754 2017-06-01 2017-06-30 0001711754 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001711754 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001711754 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001711754 inmb:TotalMember 2021-01-01 2021-03-31 0001711754 inmb:TotalMember 2020-01-01 2020-03-31 0001711754 inmb:ALSGrantMember 2021-03-31 0001711754 inmb:ALSGrantMember 2020-12-31 0001711754 2020-09-01 2020-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure Inmune Bio, Inc. false --12-31 Q1 2021 2021-03-31 10-Q 0001711754 Yes true false 001-38793 Non-accelerated Filer NV Yes false true 14932638

45340000

21967000

2190000 1686000

154000

113000

1514000

220000

15000

49213000

23986000

147000

156000

16514000

65874000

40656000

1572000

1518000

10000

34000

591000

190000

23000

34000

2196000

1776000

116000

126000

2312000

1902000

0.001

10000000

15000

13000

0.001

200000000

14932638

13481283

14932638

13481283

101466000

72105000

12000

11000

-37931000

-33375000

63562000

38754000

65874000

40656000

4000

2061000

1299000

2491000

793000

4552000

2092000

-4548000

-2092000

-8000

22000

-8000

22000

-4556000

-2070000

-0.32

-0.19

14322659

10747300

1000

-21000

-4555000

-2091000

13481283

13000

72105000

11000

-33375000

1439480

2000

28444000

28446000

11875

18000

899000

1000

-4556000

14932638

15000

101466000

12000

-37931000

10770948

11000

44834000

50000

-9000

-21276000

23610000

196000 1003000 1003000 -220000 -1012000 -1012000 216000 216000

682000

-21000

-2070000

10746948

11000

45723000

50000

-30000

-23346000

22408000

899000

682000

504000

145000

41000 -6000

1294000

170000

15000 -26000

54000

294000

-24000

29000

401000 300000 -12000 13000

-5092000

-1035000

28446000

1003000

18000

1012000

28464000

-9000

1000

-21000

23373000

-1065000

6996000

5931000

-216000

45000000

0.03

2500000

10.00

23100000

1900000

10000000

10000000 30000000

178600000

5.45

800000

1439480000

20.17

28400000

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of INmune Bio, Inc. and its subsidiaries. Intercompany transactions and balances have been eliminated. In the opinion of management, the interim financial information includes all normal recurring adjustments necessary for a fair statement of the results for the interim periods. These unaudited consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 4, 2021. Risks and Uncertainties The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict. Also, economies worldwide have also been negatively impacted by the COVID-19 pandemic, however policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain. In addition, the Company’s clinical trials have been affected by and may continue to be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment have and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients have not and others may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, the ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact the Company’s clinical trial operations. The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s service providers, suppliers, contract research organizations (“CROs”) and the Company’s clinical trials, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. Use of Estimates Preparing financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management’s estimates and assumptions. Cash and Cash Equivalents The Company considers all short-term, highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. The Company maintains cash balances that may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation limits. The Company maintains its cash deposits with major financial institutions. Research and Development Tax Incentive Receivable The Company, through its wholly-owned subsidiary in Australia (“AUS”), participates in the Australian research and development tax incentive program, such that a percentage of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives are reflected as a reduction of research and development expense. The Australian research and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information at the time. The Company, through its wholly-owned subsidiary in the United Kingdom (“UK”), participates in the research and development program provided by the United Kingdom tax relief program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United Kingdom government, and such incentives are reflected as a reduction of research and development expense. The United Kingdom research and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information at the time. Intangible Assets The Company capitalizes costs incurred in connection with in-process research and development purchased from others if the asset has alternative uses and such uses are not restricted under applicable license agreements; patent applications (principally legal fees), patent purchases, and trademarks related to its cell line as intangible assets. Acquired in-process research and development costs that do not have alternative uses are expensed as incurred. Amortization is initiated for acquired in-process research and development intangible assets when their useful lives have been determined. These acquired in-process research and development intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment. Basic and Diluted Loss per Share Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. At March 31, 2021 and 2020, the Company had potentially issuable shares as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">March 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"></td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 76%; text-align: justify">Stock options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">3,655,549</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">3,417,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Warrants</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,126,047</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,658,199</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Total</td> <td> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">5,781,596</td> <td> </td> <td> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">5,075,199</td> <td> </td></tr> </table>  Revenue Recognition The Company recognizes revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC Topic 606: (1) identify contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenues when (or as) the Company satisfies the performance obligations. The Company records the expenses related to revenue in research and development expense, in the periods such expenses were incurred. The Company records deferred revenues when cash payments are received or due in advance of performance, including amounts which are refundable. Stock-Based Compensation The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock option awards at the date of grant, which requires the input of highly subjective assumptions, including expected volatility and expected life. Changes in these inputs and assumptions can materially affect the measure of estimated fair value of our share-based compensation. These assumptions are subjective and generally require significant analysis and judgment to develop. When estimating fair value, some of the assumptions will be based on, or determined from, external data and other assumptions may be derived from our historical experience with stock-based payment arrangements. The appropriate weight to place on historical experience is a matter of judgment, based on relevant facts and circumstances. The Company accounts for forfeitures of stock options as they occur. Research and Development Research and development (“R&D”) costs are expensed as incurred. Research and development credits are recorded by the Company as a reduction of research and development costs. Major components of research and development costs include cash compensation, stock-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. The Company recognizes grants as contra research and development expense in the consolidated statement of operations on a systematic basis over the periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate. Income Taxes The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Foreign Currency Translation The Company’s financial statements are presented in the U.S. dollar (“$”), which is the Company’s reporting currency, while its functional currencies are the U.S. Dollar for its U.S. based operations, British Pound (“GBP”) for its United Kingdom-based operations and Australian Dollars (“AUD”) for its Australian-based operations. All assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income (loss). Recently Adopted Accounting Pronouncements There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on the Company´s consolidated financial position, operations or cash flows. Subsequent Events The Company evaluates events that have occurred after the balance sheet date of March 31, 2021, through the date which the financial statements are issued.

Basis of Presentation The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of INmune Bio, Inc. and its subsidiaries. Intercompany transactions and balances have been eliminated. In the opinion of management, the interim financial information includes all normal recurring adjustments necessary for a fair statement of the results for the interim periods. These unaudited consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 4, 2021

Risks and Uncertainties The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict. Also, economies worldwide have also been negatively impacted by the COVID-19 pandemic, however policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain. In addition, the Company’s clinical trials have been affected by and may continue to be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment have and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients have not and others may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, the ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact the Company’s clinical trial operations. The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s service providers, suppliers, contract research organizations (“CROs”) and the Company’s clinical trials, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations is uncertain.

Use of Estimates Preparing financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management’s estimates and assumptions.

Cash and Cash Equivalents The Company considers all short-term, highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. The Company maintains cash balances that may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation limits. The Company maintains its cash deposits with major financial institutions.

Research and Development Tax Incentive Receivable The Company, through its wholly-owned subsidiary in Australia (“AUS”), participates in the Australian research and development tax incentive program, such that a percentage of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives are reflected as a reduction of research and development expense. The Australian research and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information at the time. The Company, through its wholly-owned subsidiary in the United Kingdom (“UK”), participates in the research and development program provided by the United Kingdom tax relief program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United Kingdom government, and such incentives are reflected as a reduction of research and development expense. The United Kingdom research and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information at the time.

Intangible Assets The Company capitalizes costs incurred in connection with in-process research and development purchased from others if the asset has alternative uses and such uses are not restricted under applicable license agreements; patent applications (principally legal fees), patent purchases, and trademarks related to its cell line as intangible assets. Acquired in-process research and development costs that do not have alternative uses are expensed as incurred. Amortization is initiated for acquired in-process research and development intangible assets when their useful lives have been determined. These acquired in-process research and development intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment.

Basic and Diluted Loss per Share Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. At March 31, 2021 and 2020, the Company had potentially issuable shares as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">March 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"></td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 76%; text-align: justify">Stock options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">3,655,549</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">3,417,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Warrants</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,126,047</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,658,199</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Total</td> <td> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">5,781,596</td> <td> </td> <td> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">5,075,199</td> <td> </td></tr> </table>

Revenue Recognition The Company recognizes revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC Topic 606: (1) identify contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenues when (or as) the Company satisfies the performance obligations. The Company records the expenses related to revenue in research and development expense, in the periods such expenses were incurred. The Company records deferred revenues when cash payments are received or due in advance of performance, including amounts which are refundable.

Stock-Based Compensation The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock option awards at the date of grant, which requires the input of highly subjective assumptions, including expected volatility and expected life. Changes in these inputs and assumptions can materially affect the measure of estimated fair value of our share-based compensation. These assumptions are subjective and generally require significant analysis and judgment to develop. When estimating fair value, some of the assumptions will be based on, or determined from, external data and other assumptions may be derived from our historical experience with stock-based payment arrangements. The appropriate weight to place on historical experience is a matter of judgment, based on relevant facts and circumstances. The Company accounts for forfeitures of stock options as they occur.

Research and Development Research and development (“R&D”) costs are expensed as incurred. Research and development credits are recorded by the Company as a reduction of research and development costs. Major components of research and development costs include cash compensation, stock-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. The Company recognizes grants as contra research and development expense in the consolidated statement of operations on a systematic basis over the periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate.

Income Taxes The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Foreign Currency Translation The Company’s financial statements are presented in the U.S. dollar (“$”), which is the Company’s reporting currency, while its functional currencies are the U.S. Dollar for its U.S. based operations, British Pound (“GBP”) for its United Kingdom-based operations and Australian Dollars (“AUD”) for its Australian-based operations. All assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income (loss).

Subsequent Events The Company evaluates events that have occurred after the balance sheet date of March 31, 2021, through the date which the financial statements are issued.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">March 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"></td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 76%; text-align: justify">Stock options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">3,655,549</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">3,417,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Warrants</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,126,047</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,658,199</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Total</td> <td> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">5,781,596</td> <td> </td> <td> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">5,075,199</td> <td> </td></tr> </table>

3655549

3417000

2126047

1658199

5781596

5075199

NOTE 4 – RESEARCH AND DEVELOPMENT ACTIVITY According to UK tax law, the Company is allowed an R&D tax credit that reduces a company’s tax bill in the UK for expenses incurred in R&D subject to certain requirements. The Company’s UK subsidiary submits R&D tax credit requests annually for research and development expenses incurred. At March 31, 2021 and December 31, 2020, the Company recorded a research and development tax credit receivable in the amount of $1,104,000 and $833,000, respectively. During the three months ended March 31, 2021 and 2020, the Company received $0 of R&D tax credit reimbursements from the UK. According to AUS tax law, the Company is allowed an R&D tax credit that reduces a company’s tax bill in AUS for expenses incurred in R&D subject to certain requirements. The Company’s Australian subsidiary submits R&D tax credit requests annually for research and development expenses incurred. At March 31, 2021 and December 31, 2020, the Company recorded a research and development tax credit receivable of $1,086,000 and $853,000, respectively, for R&D expenses incurred in Australia. During the three months ended March 31, 2021 and 2020, the Company received $0 R&D tax credit reimbursements from Australia. Xencor, Inc. License Agreement On October 3, 2017, the Company entered into a license agreement (“Xencor License Agreement”) with Xencor, Inc. (“Xencor”), which has discovered and developed a proprietary biological molecule that inhibits soluble tumor necrosis factor. Pursuant to the license agreement, Xencor granted the Company an exclusive worldwide, royalty-bearing license in licensed patent rights, licensed know-how and licensed materials (as defined in the license agreement) to make, develop, use, sell and import any pharmaceutical product that comprises, contains, or incorporates Xencor’s proprietary protein known as “XPro1595” that inhibits soluble tumor necrosis factor (or all modifications, formulations and variants of the licensed protein that specifically bind soluble tumor necrosis factor) alone or in combination with one or more active ingredients, in any dosage or formulation (“Licensed Products”). The Company believes the protein has numerous medical applications. Such additional alternative applications of the technology are available under the Xencor License Agreement. In connection with the Xencor License Agreement, the Company paid Xencor a one-time non-creditable and non-refundable fee of $100,000 and issued Xencor 1,585,000 shares of the Company’s common stock with a fair value of $12,221,000. In addition, the Company issued Xencor fully vested warrants with a fair value of $4,193,000 to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase. The aggregate purchase price for the full exercise of the option is $10,000,000 which purchase price shall be pro-rated for any partial exercise of the warrant. In August 2018, the Company entered into a First Amendment to Stock Issuance Agreement. Pursuant to the amendment, the purchase price for the additional shares may only be paid by cash. The warrants expire on October 3, 2023. The Company recorded $16,514,000 for the acquisition of intangible assets for the in-process research and development as the fair value of the cash, stock and warrants on the date of the License Agreement acquisition in accordance with Accounting Standards Codification 730 – Research and Development. The Company has the license rights to pursue alternative applications of the technology as part of its future development plans. The Company also agreed to pay Xencor a royalty on Net Sales of all Licensed Products in a given calendar year, which are payable on a country-by- country and licensed product by licensed product basis until the date that is the later of (a) the expiration of the last to expire valid claim covering such Licensed Product in such country or (b) ten years following the first sale to a third party of the licensed product in such country. Under the Xencor License Agreement, the Company also agreed to pay Xencor a percentage of any sublicensing revenue that it receives. INKmune License Agreement On October 29, 2015, the Company entered into an exclusive license agreement (the “INKmune License Agreement”) with Immune Ventures, LLC (“Immune Ventures”). Pursuant to the INKmune License Agreement, the Company was granted exclusive worldwide rights to the patents, including rights to incorporate any improvements or additions to the patents that may be developed in the future. In consideration for the patent rights, the Company agreed to the following milestone payments (of which none have been met as of March 31, 2021): (in thousands) <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Each Phase I initiation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Each Phase II initiation</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Each Phase III initiation</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">350</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Each NDA/EMA filing</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Each NDA/EMA awarded</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9,000</td><td style="text-align: left"> </td></tr> </table> In addition, the Company agreed to pay Immune Ventures a royalty of 1% of net sales during the life of each patent granted to the Company. RJ Tesi, the Company’s President and a member of our Board of Directors, David Moss, its Chief Financial Officer and Treasurer and Mark Lowdell, its Chief Scientific Officer, are the owners of Immune Ventures. As of March 31, 2021, no sales had occurred under this license. The term of the agreement began on October 29, 2015 and, if not terminated sooner pursuant to the agreement, ends on a country-by-country basis on the date of the expiration of the last to expire patent rights where patent rights exists. Upon the termination of the agreement, we shall have a fully paid up, perpetual, royalty-free license without further obligation to Immune Ventures. The agreement can be terminated by Immune Ventures if, after 60 days from the Company’s receipt of notice that the Company has not made a payment under the agreement, and the Company still does not make this payment. On July 20, 2018, the parties amended the agreement under which the Company was required achieve milestones pursuant to the agreement. On October 30, 2020, the parties executed an additional amendment to the agreement under which the Company is required to achieve the following milestones: Initiation of Phase 1 clinical or equivalent trials by October 29, 2021 Initiation of Phase II clinical trials or equivalent by October 29, 2023 Initiation of Phase III clinical trials or equivalent by October 29, 2025 Filing of NDA or equivalent by October 29, 2026 or equivalent If the Company doesn’t achieve the above milestones, it is required to negotiate in good faith with Immune Ventures to determine how it can either remedy the failure or achieve an alternate development. If the Company fails to make any required efforts, or if the efforts do not remedy the situation within 60 days of written notice by Immune Ventures, then Immune Ventures may provide notice to terminate the license or convert it to a non-exclusive license. University of Pittsburg License Agreement On October 3, 2017, the Company entered into an Assignment and Assumption Agreement with Immune Ventures related to intellectual property licensed from the University of Pittsburgh. Pursuant to the Assignment and Assumption Agreement (“Assignment Agreement”), Immune Ventures assigned all of its rights, obligations and liabilities under an Exclusive License Agreement between the University of Pittsburgh – Of the Commonwealth System of Higher Education (“Licensor”) and Immune Ventures to INmune Bio (“Licensee”), (the “PITT Agreement”). Consideration under the PITT Agreement includes: (i) annual maintenance fees, (ii) royalty payments based on the sale of products making use of the licensed technology, and (iii) milestone payments. Annual maintenance fees under the PITT Agreement include the following: (in thousands) <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">June 26 of each year 2021-2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">June 26 of each year 2023-2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">June 26 of each year 2025 until first commercial sale</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">25</td><td style="text-align: left"> </td></tr> </table> Upon first commercial sale of a product making use of the licensed technology under the PITT Agreement, the Licensee is required to pay royalties equal to 2.5% of Net Sales each calendar quarter. Moreover, under the PITT Agreement the Licensee is required to make milestone payments as follows: (in thousands) <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify"> Each Phase I initiation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Each Phase III initiation</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">First commercial sale of product making use of licensed technology</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,250</td><td style="text-align: left"> </td></tr> </table> The Company had no amounts owed pursuant to the PITT Agreement as of March 31, 2021. The PITT Agreement expires upon the earlier of: (i) expiration of the last claim of the Patent Rights (as defined in the PITT Agreement) forming the subject matter of the PITT Agreement; or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037). The Licensee may terminate the PITT Agreement upon 3 months prior written notice provided all payments under the license are current. The Licensor may terminate the PITT Agreement upon written notice if: (i) Licensee defaults as to performance of material obligations which have not been cured within 60 days after receiving written notice; or (ii) Licensee ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of debtors. University College London License Agreement – MSC On July 19, 2019, the Company entered into license agreement with UCL Business PLC (“UCLB”) with a ten (10) year term. Pursuant to the license agreement, the Company acquired an exclusive license (and a right to sub-license) to the technology and know-how relating to an isolation and commercial scale expansion methodology of GMP grade human umbilical cord mesenchymal stem/stromal cells (“MSC”). In exchange for the license agreement, the Company paid UCLB an initial license fee of $10,000 and shall pay annual licensing fees of approximately $13,000 per year for the remaining term of the agreement. The Company will pay UCLB a royalty of 3-3.5%% of the net sales value (as defined in the agreement) of all licensed products sold or used by the Company. In the event the Company sub-licenses the technology and know-how, the Company will pay UCLB a royalty of twelve (12) percent of consideration (cash or non-cash) received by the Company in relation to the development or sub-licensing of any of the technology and know-how.

1104000

833000

1086000

853000

100000

1585000

12221000

4193000

0.10 10000000

16514000

0.01 0.025 The PITT Agreement expires upon the earlier of: (i) expiration of the last claim of the Patent Rights (as defined in the PITT Agreement) forming the subject matter of the PITT Agreement; or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037). In exchange for the license agreement, the Company paid UCLB an initial license fee of $10,000 and shall pay annual licensing fees of approximately $13,000 per year for the remaining term of the agreement. The Company will pay UCLB a royalty of 3-3.5%% of the net sales value (as defined in the agreement) of all licensed products sold or used by the Company. In the event the Company sub-licenses the technology and know-how, the Company will pay UCLB a royalty of twelve (12) percent of consideration (cash or non-cash) received by the Company in relation to the development or sub-licensing of any of the technology and know-how.

25000

250000

350000

1000000

9000000

5000

10000

25000

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify"> Each Phase I initiation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Each Phase III initiation</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">First commercial sale of product making use of licensed technology</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,250</td><td style="text-align: left"> </td></tr> </table>

50000

500000

1250000

P61M

The lessor may extend its lease for an additional 5 years, and, if it does, the Company may also extend its sublease for 5 years.

13000

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Right-of-use asset – related party</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">147</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating lease, current liability – related party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Long-term operating lease liability – related party</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">116</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total lease liability</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">139</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted-average remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.2 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted-average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.00</td><td style="text-align: left">%</td></tr> </table>

139000

P3Y73D

0.1000

10000

34000

15000

88000

79000

216000

NOTE 7 – STOCKHOLDERS’ EQUITY Lincoln Park On May 15, 2019, the Company entered into both a securities purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Under the terms and subject to the conditions of the securities purchase agreement, the Company had the right to sell to Lincoln Park, and Lincoln Park was obligated to purchase, up to $20.0 million in shares of the Company’s common stock, subject to certain limitations, over the 24-month period that commenced on May 15, 2019. During the three months ended March 31, 2020, the Company issued 196,000 shares of its common stock to Lincoln Park for approximately $1.0 million of cash. During April 2021, the Company terminated the securities purchase agreement with Lincoln Park. Purchase and retirement of common stock During January 2020, the Company purchased and cancelled 220,000 shares of its common stock from a shareholder in exchange for approximately $1.0 million of cash. Common Stock – At the Market Offering During the three months ended March 31, 2021, the Company sold 1,439,480 shares of its common stock for aggregate gross proceeds of approximately $29.0 million (net proceeds of approximately $28.4 million) under the 2020 ATM program. The Company paid BTIG commissions and fees of $582,000 in connection with the sale of these shares. Stock options During January 2021, the Company granted certain employees and directors options to purchase 198,549 shares of its common stock pursuant to the 2017 and 2019 Incentive Stock Plans. The stock options have a fair value of approximately $4.2 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 0.78% based on the applicable US Treasury bill rate (2) expected life of 6.0 - 6.25 years, (3) expected volatility of approximately 113% - 114% based on the trading history of similar companies, and (4) zero expected dividends. The following table summarizes stock option activity during the three months ended March 31, 2021: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands, except share and per share amounts)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted- average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted-average Remaining Contractual Term (years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Outstanding at January 1, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,457,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.82</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8.05</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">39,405</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">198,549</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">24.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Options cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Outstanding at March 31, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3,655,549</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.85</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">7.91</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">20,945</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Exercisable at March 31, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,415,889</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.54</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">7.42</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">12,906</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> During the three months ended March 31, 2021 and 2020, the Company recognized stock-based compensation expense of approximately $0.9 million and $0.7 million, respectively, related to the vesting of stock options. As of March 31, 2021, there was approximately $7.3 million of total unrecognized compensation cost related to non-vested stock options which is expected to be recognized over a weighted-average period of 2.72 years. Warrants In connection with the Company’s initial public offering in February 2019, the Company issued warrants to the placement agents to purchase the Company’s common stock at an exercise price of $9.60 per common share, which warrants are exercisable until December 19, 2023. At March 31, 2021, 34,835 of these warrants are outstanding and the intrinsic value is $79,000. In October 2017, in connection with the Xencor License Agreement, the Company issued fully vested warrants to purchase an additional number of shares of common stock equal to 10% of the fully diluted Company shares immediately following such purchase. See Note 4. These warrants had an intrinsic value of approximately $14.6 million as of March 31, 2021. On June 30, 2017, the Company issued fully vested warrants to purchase 31,667 shares of the Company’s common stock to a third party in conjunction with the common stock sold for cash. The warrants have a $1.50 exercise price and expire on June 30, 2022. During the three months ended March 31, 2021, 11,875 of these warrants were exercised for cash proceeds of $18,000. At March 31, 2021, 19,792 of these warrants are outstanding, with an intrinsic value of $205,000. Stock-based Compensation by Class of Expense The following summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three months ended March 31, 2021 and 2020 respectively: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-style: italic">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">186</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">139</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">713</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">543</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">899</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">682</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Shareholder Rights Agreement On December 30, 2020, the Board of Directors (the “Board”) of the Company approved and adopted a Rights Agreement, dated as of December 30, 2020, by and between the Company and VStock Transfer, LLC, as rights agent, pursuant to which the Board declared a dividend of one preferred share purchase right (each, a “Right”) for each outstanding share of the Company’s common stock held by stockholders as of the close of business on January 11, 2021. When exercisable, each right initially would represent the right to purchase from the Company one one-thousandth of a share of a newly designated series of preferred stock, Series A Junior Participating Preferred Stock, par value $0.001 per share, of the Company, at an exercise price of $300.00 per one one-thousandth of a Series A Junior Participating Preferred Share, subject to adjustment. Subject to various exceptions, the Rights become exercisable in the event any person (excluding certain exempted or grandfathered persons) becomes the beneficial owner of twenty percent or more of the Company’s common stock without the approval of the Board. The Rights are scheduled to expire on December 30, 2021.

Under the terms and subject to the conditions of the securities purchase agreement, the Company had the right to sell to Lincoln Park, and Lincoln Park was obligated to purchase, up to $20.0 million in shares of the Company’s common stock, subject to certain limitations, over the 24-month period that commenced on May 15, 2019.

20000000

196000

1.0

220000

1.0

1439480

29.0

28.4

582000

198549 4.2

0.0078

P6Y

P6Y3M

1.13

1.14

0.9

0.7

7.3

P2Y262D

9.60

34835

79000 0.10 14.6

31667000000

1.50

2022-06-30

11875

18000

19792

205000 the Company one one-thousandth of a share of a newly designated series of preferred stock, Series A Junior Participating Preferred Stock, par value $0.001 per share, of the Company, at an exercise price of $300.00 per one one-thousandth of a Series A Junior Participating Preferred Share, subject to adjustment. Subject to various exceptions, the Rights become exercisable in the event any person (excluding certain exempted or grandfathered persons) becomes the beneficial owner of twenty percent or more of the Company’s common stock without the approval of the Board.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands, except share and per share amounts)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted- average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted-average Remaining Contractual Term (years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Outstanding at January 1, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,457,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.82</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8.05</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">39,405</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">198,549</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">24.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Options cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Outstanding at March 31, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3,655,549</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.85</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">7.91</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">20,945</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Exercisable at March 31, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,415,889</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.54</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">7.42</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">12,906</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

3457000

5.82

P8Y18D

39405000

198549

24.82

3655549

6.85

P7Y332D

20945000

2415889

6.54

P7Y153D

12906000

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-style: italic">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">186</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">139</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">713</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">543</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">899</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">682</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

186000

139000

713000

543000

899000

682000

100000

300000

200000

100000

the Company was awarded a grant of up to $2.9 million from the National Institutes of Health (“NIH”). The grant will support a Phase 2 study of XPro1595 in patients with treatment resistant depression. As of March 31, 2021, the Company has not received any proceeds pursuant to this grant.

EX-101.SCH 7 inmb-20210331.xsd XBRL SCHEMA FILE 001 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated statements of operations and comprehensive loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated statements of operations and comprehensive loss (Unaudited) Alternate 0 link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statement of Changes in Stockholders’ Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Organization and Description of Business link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Liquidity link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Research and Development Activity link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Lease link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Collaborative Agreements link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Research and Development Activity (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Lease (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Liquidity (Details) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of potentially issuable shares link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Research and Development Activity (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Research and Development Activity (Details) - Schedule of consideration of annual maintenance fees under the PITT agreement link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Research and Development Activity (Details) - Schedule of licensee required to make milestone payments link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Lease (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Lease (Details) - Schedule of right-of-use assets and liabilities for operating lease link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Stockholders' Equity (Details) - Schedule of stock option activity link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Stockholders' Equity (Details) - Schedule of stock-based compensation expense link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Collaborative Agreements (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 inmb-20210331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 inmb-20210331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 inmb-20210331_lab.xml XBRL LABEL FILE Statement of Financial Position [Abstract] TOTAL CURRENT ASSETS TOTAL ASSETS TOTAL CURRENT LIABILITIES TOTAL LIABILITIES TOTAL STOCKHOLDERS’ EQUITY Balance Balance TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Income Statement [Abstract] Total operating expenses LOSS FROM OPERATIONS Total other (expense) income NET LOSS Net loss Weighted average number of common shares outstanding – basic and diluted (in Shares) Other comprehensive income (loss) – foreign currency translation Total comprehensive loss Statement of Stockholders' Equity [Abstract] Balance (in Shares) Balance (in Shares) Equity Components [Axis] Statement of Cash Flows [Abstract] Net cash used in operating activities Net cash provided by (used in) financing activities NET INCREASE (DECREASE) IN CASH CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT END OF PERIOD Cash and cash equivalents Accounting Policies [Abstract] Liquidity Disclosure [Abstract] Schedule of potentially issuable shares [Abstract] Sale of Stock [Axis] Research and Development [Abstract] Schedule of milestone payments in consideration for the patent rights [Abstract] Milestone Payments [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Related Party [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Schedule of consideration of annual maintenance fees under the PITT agreement [Abstract] Commercial Sale [Axis] Product and Service [Axis] Schedule of licensee required to make milestone payments [Abstract] ASU 2016-02 Transition [Abstract] Schedule of right-of-use assets and liabilities for operating lease [Abstract] Total lease liability Related Party Transactions [Abstract] Stockholders' Equity Note [Abstract] Schedule of stock option activity [Abstract] Number of shares, Outstanding Weighted- average Exercise Price, Outstanding Weighted- average Exercise Price, Outstanding Aggregate Intrinsic Value, Outstanding Aggregate Intrinsic Value, Outstanding Number of shares, Outstanding Schedule of stock-based compensation expense [Abstract] Income Statement Location [Axis] Organization, Consolidation and Presentation of Financial Statements [Abstract] Entity Registrant Name Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Document Type Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Current Reporting Status Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Filer Category Entity Incorporation, State or Country Code Entity Interactive Data Current Entity Shell Company Entity Small Business ASSETS CURRENT ASSETS Research and development tax credit receivable Other tax receivable Prepaid expenses Prepaid expenses – related party Operating lease – right of use asset – related party Right-of-use asset – related party Acquired in-process research and development intangible assets LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities Accounts payable and accrued liabilities – related parties Amount of company owed to UCL Consultants Limited Deferred liabilities Operating lease, current liability – related party Long-term operating lease liability – related party COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding Preferred stock par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, $0.001 par value, 200,000,000 shares authorized, 14,932,638 and 13,481,283 shares issued and outstanding, respectively Common stock par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock issued (in Shares) Common stock, shares outstanding Additional paid-in capital Accumulated other comprehensive income Accumulated deficit REVENUE OPERATING EXPENSES General and administrative Research and development Payment for medical research performed expense OTHER (EXPENSE) INCOME Other (expense) income Net loss per common share – basic and diluted (in Dollars per share) COMPREHENSIVE LOSS Issuance of common stock for cash Issuance of value Issuance of common stock for cash (in Shares) Issuance of shares (in Shares) Exercise of warrants Exercise of warrants (in Shares) Stock-based compensation Gain/Loss on foreign currency translation Issuance of common stock and warrants for cash, net Issuance of common stock and warrants for cash, net (in Shares) Acquisition and retirement of common stock Acquisition and retirement of common stock (in Shares) Capital contribution CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Total Changes in operating assets and liabilities: Accounts payable and accrued liabilities Accounts payable and accrued liabilities – related parties Deferred liabilities Operating lease liability – related party CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from sale of common stock Net proceeds from common stock Net proceeds from the exercise of warrants Impact on cash from foreign currency translation SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: NONCASH INVESTING AND FINANCING ACTIVITIES: Research and development tax credit receivable Other tax receivable Prepaid expenses Prepaid expenses – related party Purchase of common stock Cash paid for income taxes Cash paid for interest expense Capital contribution Capital contribution Common Stock Common Stock [Member] Additional Paid-In Capital Accumulated Other Comprehensive Income LossLoss Accumulated Deficit Common Stock Issuable ORGANIZATION AND DESCRIPTION OF BUSINESS LIQUIDITY SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Schedule of potentially issuable shares Total RESEARCH AND DEVELOPMENT ACTIVITY Schedule of milestone payments in consideration for the patent rights Payment method of milestone payments Schedule of consideration of annual maintenance fees under the PITT agreement Annual maintenance fees until first commercial sale Schedule of licensee required to make milestone payments LEASE Schedule of right-of-use assets and liabilities for operating lease Weighted-average remaining lease term Weighted-average discount rate RELATED PARTY TRANSACTIONS STOCKHOLDERS’ EQUITY Schedule of stock option activity Weighted-average Remaining Contractual Term (years), Outstanding Number of shares, Options granted Weighted- average Exercise Price, Options granted Number of shares, Options exercised Weighted- average Exercise Price, Options exercised Number of shares, Options cancelled Weighted- average Exercise Price, Options cancelled Weighted-average Remaining Contractual Term (years), Outstanding Number of shares, Exercisable at September 30, 2020 Weighted- average Exercise Price, Exercisable at September 30, 2020 Weighted-average Remaining Contractual Term (years), Exercisable at September 30, 2020 Aggregate Intrinsic Value, Exercisable at September 30, 2020 Schedule of stock-based compensation expense COLLABORATIVE AGREEMENTS Stock options [Member] Warrants [Member] Warrant [Member] Common Stock [Member] Each Phase I initiation [Member] Patents [Member] Immune Ventures LLc [Member] Inkmune License Agreement [Member] Each Phase II initiation [Member] Each Phase III initiation [Member] EX-101.PRE 11 inmb-20210331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2021	May 05, 2021
Document Information Line Items
Entity Registrant Name	Inmune Bio, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		14,932,638
Amendment Flag	false
Entity Central Index Key	0001711754
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity File Number	001-38793
Entity Incorporation, State or Country Code	NV
Entity Interactive Data Current	Yes

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 45,340	$ 21,967
Research and development tax credit receivable	2,190	1,686
Other tax receivable	154	113
Prepaid expenses	1,514	220
Prepaid expenses – related party	15
TOTAL CURRENT ASSETS	49,213	23,986
Operating lease – right of use asset – related party	147	156
Acquired in-process research and development intangible assets	16,514	16,514
TOTAL ASSETS	65,874	40,656
CURRENT LIABILITIES
Accounts payable and accrued liabilities	1,572	1,518
Accounts payable and accrued liabilities – related parties	10	34
Deferred liabilities	591	190
Operating lease, current liability – related party	23	34
TOTAL CURRENT LIABILITIES	2,196	1,776
Long-term operating lease liability – related party	116	126
TOTAL LIABILITIES	2,312	1,902
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.001 par value, 200,000,000 shares authorized, 14,932,638 and 13,481,283 shares issued and outstanding, respectively	15	13
Additional paid-in capital	101,466	72,105
Accumulated other comprehensive income	12	11
Accumulated deficit	(37,931)	(33,375)
TOTAL STOCKHOLDERS’ EQUITY	63,562	38,754
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 65,874	$ 40,656

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	14,932,638	13,481,283
Common stock, shares outstanding	14,932,638	13,481,283

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated statements of operations and comprehensive loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
REVENUE	$ 4
OPERATING EXPENSES
General and administrative	2,061	1,299
Research and development	2,491	793
Total operating expenses	4,552	2,092
LOSS FROM OPERATIONS	(4,548)	(2,092)
OTHER (EXPENSE) INCOME
Other (expense) income	(8)	22
Total other (expense) income	(8)	22
NET LOSS	$ (4,556)	$ (2,070)
Net loss per common share – basic and diluted (in Dollars per share)	$ (0.32)	$ (0.19)
Weighted average number of common shares outstanding – basic and diluted (in Shares)	14,322,659	10,747,300
COMPREHENSIVE LOSS
Net loss	$ (4,556)	$ (2,070)
Other comprehensive income (loss) – foreign currency translation	1	(21)
Total comprehensive loss	$ (4,555)	$ (2,091)

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Changes in Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income LossLoss	Accumulated Deficit	Common Stock Issuable	Total
Balance at Dec. 31, 2019	$ 11	$ 44,834	$ (9)	$ (21,276)	$ 50	$ 23,610
Balance (in Shares) at Dec. 31, 2019	10,770,948
Issuance of common stock and warrants for cash, net		1,003				1,003
Issuance of common stock and warrants for cash, net (in Shares)	196,000
Acquisition and retirement of common stock		(1,012)				(1,012)
Acquisition and retirement of common stock (in Shares)	(220,000)
Capital contribution		216				216
Stock-based compensation		682				682
Gain/Loss on foreign currency translation			(21)			(21)
Net loss				(2,070)		(2,070)
Balance at Mar. 31, 2020	$ 11	45,723	(30)	(23,346)	$ 50	22,408
Balance (in Shares) at Mar. 31, 2020	10,746,948
Balance at Dec. 31, 2020	$ 13	72,105	11	(33,375)		38,754
Balance (in Shares) at Dec. 31, 2020	13,481,283
Issuance of common stock for cash	$ 2	28,444				28,446
Issuance of common stock for cash (in Shares)	1,439,480
Exercise of warrants		18				18
Exercise of warrants (in Shares)	11,875
Stock-based compensation		899				899
Gain/Loss on foreign currency translation			1			1
Net loss				(4,556)		(4,556)
Balance at Mar. 31, 2021	$ 15	$ 101,466	$ 12	$ (37,931)		$ 63,562
Balance (in Shares) at Mar. 31, 2021	14,932,638

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,556)	$ (2,070)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	899	682
Changes in operating assets and liabilities:
Research and development tax credit receivable	(504)	(145)
Other tax receivable	(41)	6
Prepaid expenses	(1,294)	(170)
Prepaid expenses – related party	(15)	26
Accounts payable and accrued liabilities	54	294
Accounts payable and accrued liabilities – related parties	(24)	29
Deferred liabilities	401	300
Operating lease liability – related party	(12)	13
Net cash used in operating activities	(5,092)	(1,035)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of common stock	28,446	1,003
Net proceeds from the exercise of warrants	18
Purchase of common stock		(1,012)
Net cash provided by (used in) financing activities	28,464	(9)
Impact on cash from foreign currency translation	1	(21)
NET INCREASE (DECREASE) IN CASH	23,373	(1,065)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	21,967	6,996
CASH AND CASH EQUIVALENTS AT END OF PERIOD	45,340	5,931
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash paid for income taxes
Cash paid for interest expense
NONCASH INVESTING AND FINANCING ACTIVITIES:
Capital contribution		$ 216

XML 18 R7.htm IDEA: XBRL DOCUMENT

Organization and Description of Business

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

ORGANIZATION AND DESCRIPTION OF BUSINESS

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

XML 19 R8.htm IDEA: XBRL DOCUMENT

Liquidity

3 Months Ended

Mar. 31, 2021

Liquidity Disclosure [Abstract]

LIQUIDITY

NOTE 2 – LIQUIDITY

To meet its current and future obligations the Company has taken the following steps to capitalize the business and achieve its business plan:

●

XML 20 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Risks and Uncertainties

Use of Estimates

Cash and Cash Equivalents

Research and Development Tax Incentive Receivable

Intangible Assets

Basic and Diluted Loss per Share

At March 31, 2021 and 2020, the Company had potentially issuable shares as follows:

	March 31,
	2021		2020
Stock options		3,655,549		3,417,000
Warrants		2,126,047		1,658,199
Total		5,781,596		5,075,199

Revenue Recognition

The Company records deferred revenues when cash payments are received or due in advance of performance, including amounts which are refundable.

Stock-Based Compensation

Research and Development

Income Taxes

Foreign Currency Translation

Recently Adopted Accounting Pronouncements

Subsequent Events

The Company evaluates events that have occurred after the balance sheet date of March 31, 2021, through the date which the financial statements are issued.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Research and Development Activity

3 Months Ended

Mar. 31, 2021

Research and Development [Abstract]

RESEARCH AND DEVELOPMENT ACTIVITY

NOTE 4 – RESEARCH AND DEVELOPMENT ACTIVITY

Xencor, Inc. License Agreement

Under the Xencor License Agreement, the Company also agreed to pay Xencor a percentage of any sublicensing revenue that it receives.

INKmune License Agreement

(in thousands)

Each Phase I initiation	$	25
Each Phase II initiation	$	250
Each Phase III initiation	$	350
Each NDA/EMA filing	$	1,000
Each NDA/EMA awarded	$	9,000

Initiation of Phase 1 clinical or equivalent trials by October 29, 2021

Initiation of Phase II clinical trials or equivalent by October 29, 2023

Initiation of Phase III clinical trials or equivalent by October 29, 2025

Filing of NDA or equivalent by October 29, 2026 or equivalent

University of Pittsburg License Agreement

Consideration under the PITT Agreement includes: (i) annual maintenance fees, (ii) royalty payments based on the sale of products making use of the licensed technology, and (iii) milestone payments.

Annual maintenance fees under the PITT Agreement include the following:

(in thousands)

June 26 of each year 2021-2022	$	5
June 26 of each year 2023-2024	$	10
June 26 of each year 2025 until first commercial sale	$	25

Upon first commercial sale of a product making use of the licensed technology under the PITT Agreement, the Licensee is required to pay royalties equal to 2.5% of Net Sales each calendar quarter.

Moreover, under the PITT Agreement the Licensee is required to make milestone payments as follows:

(in thousands)

Each Phase I initiation

Each Phase III initiation

500

First commercial sale of product making use of licensed technology

1,250

The Company had no amounts owed pursuant to the PITT Agreement as of March 31, 2021.

University College London License Agreement – MSC

XML 22 R11.htm IDEA: XBRL DOCUMENT

Lease

3 Months Ended

Mar. 31, 2021

Leases [Abstract]

LEASE

NOTE 5 – LEASE

(in thousands, except years and rate)

Right-of-use asset – related party	$	147

Operating lease, current liability – related party	$	23
Long-term operating lease liability – related party		116
Total lease liability	$	139

Weighted-average remaining lease term		3.2 years

Weighted-average discount rate		10.00	%

XML 23 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Mar. 31, 2021

RELATED PARTY TRANSACTIONS

NOTE 6 – RELATED PARTY TRANSACTIONS

UCL

CTI

XML 24 R13.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Mar. 31, 2021

Stockholders' Equity Note [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 7 – STOCKHOLDERS’ EQUITY

Lincoln Park

During April 2021, the Company terminated the securities purchase agreement with Lincoln Park.

Purchase and retirement of common stock

During January 2020, the Company purchased and cancelled 220,000 shares of its common stock from a shareholder in exchange for approximately $1.0 million of cash.

Common Stock – At the Market Offering

Stock options

The following table summarizes stock option activity during the three months ended March 31, 2021:

(in thousands, except share and per share amounts)	Number of Shares		Weighted- average Exercise Price		Weighted-average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at January 1, 2021		3,457,000	$	5.82		8.05	$	39,405
Options granted		198,549	$	24.82		-		-
Options exercised		-	$	-		-		-
Options cancelled		-	$	-		-		-
Outstanding at March 31, 2021		3,655,549	$	6.85		7.91	$	20,945
Exercisable at March 31, 2021		2,415,889	$	6.54		7.42	$	12,906

Warrants

Stock-based Compensation by Class of Expense

The following summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three months ended March 31, 2021 and 2020 respectively:

(in thousands)	Three Months Ended March 31, 2021		Three Months Ended March 31, 2020
Research and development	$	186	$	139
General and administrative		713		543
Total	$	899	$	682

Shareholder Rights Agreement

XML 25 R14.htm IDEA: XBRL DOCUMENT

Collaborative Agreements

3 Months Ended

Mar. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

COLLABORATIVE AGREEMENTS

NOTE 8 – COLLABORATIVE AGREEMENTS

XML 26 R15.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Risks and Uncertainties

Risks and Uncertainties

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Research and Development Tax Incentive Receivable

Research and Development Tax Incentive Receivable

Intangible Assets

Intangible Assets

Basic and Diluted Loss per Share

Basic and Diluted Loss per Share

At March 31, 2021 and 2020, the Company had potentially issuable shares as follows:

	March 31,
	2021		2020
Stock options		3,655,549		3,417,000
Warrants		2,126,047		1,658,199
Total		5,781,596		5,075,199

Revenue Recognition

Revenue Recognition

The Company records deferred revenues when cash payments are received or due in advance of performance, including amounts which are refundable.

Stock-Based Compensation

Stock-Based Compensation

Research and Development

Research and Development

Income Taxes

Income Taxes

Foreign Currency Translation

Foreign Currency Translation

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Subsequent Events

Subsequent Events

The Company evaluates events that have occurred after the balance sheet date of March 31, 2021, through the date which the financial statements are issued.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Schedule of potentially issuable shares

	March 31,
	2021		2020
Stock options		3,655,549		3,417,000
Warrants		2,126,047		1,658,199
Total		5,781,596		5,075,199

XML 28 R17.htm IDEA: XBRL DOCUMENT

Research and Development Activity (Tables)

3 Months Ended

Mar. 31, 2021

Research and Development [Abstract]

Schedule of milestone payments in consideration for the patent rights

Each Phase I initiation	$	25
Each Phase II initiation	$	250
Each Phase III initiation	$	350
Each NDA/EMA filing	$	1,000
Each NDA/EMA awarded	$	9,000

Schedule of consideration of annual maintenance fees under the PITT agreement

June 26 of each year 2021-2022	$	5
June 26 of each year 2023-2024	$	10
June 26 of each year 2025 until first commercial sale	$	25

Schedule of licensee required to make milestone payments

Each Phase I initiation

Each Phase III initiation

500

First commercial sale of product making use of licensed technology

1,250

XML 29 R18.htm IDEA: XBRL DOCUMENT

Lease (Tables)

3 Months Ended

Mar. 31, 2021

Leases [Abstract]

Schedule of right-of-use assets and liabilities for operating lease

Right-of-use asset – related party	$	147

Operating lease, current liability – related party	$	23
Long-term operating lease liability – related party		116
Total lease liability	$	139

Weighted-average remaining lease term		3.2 years

Weighted-average discount rate		10.00	%

XML 30 R19.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2021

Stockholders' Equity Note [Abstract]

Schedule of stock option activity

(in thousands, except share and per share amounts)	Number of Shares		Weighted- average Exercise Price		Weighted-average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at January 1, 2021		3,457,000	$	5.82		8.05	$	39,405
Options granted		198,549	$	24.82		-		-
Options exercised		-	$	-		-		-
Options cancelled		-	$	-		-		-
Outstanding at March 31, 2021		3,655,549	$	6.85		7.91	$	20,945
Exercisable at March 31, 2021		2,415,889	$	6.54		7.42	$	12,906

Schedule of stock-based compensation expense

(in thousands)	Three Months Ended March 31, 2021		Three Months Ended March 31, 2020
Research and development	$	186	$	139
General and administrative		713		543
Total	$	899	$	682

XML 31 R20.htm IDEA: XBRL DOCUMENT

Liquidity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Jul. 31, 2020	Apr. 30, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Liquidity (Details) [Line Items]
Accumulated deficit			$ (37,931)		$ (33,375)
Offering program common stock value			$ 45,000
Gross proceeds from the sale of shares, percentage			3.00%
Net proceeds from common stock			$ 28,446	$ 1,003
Sales Agreement [Member]
Liquidity (Details) [Line Items]
Sale of common stock shares (in Shares)			1,439,480,000		178,600,000
Average price per share (in Dollars per share)			$ 20.17		$ 5.45
Net proceeds from common stock			$ 28,400		$ 800
Sales Agreement [Member] \| Minimum [Member]
Liquidity (Details) [Line Items]
Aggregate offering price		$ 10,000
Sales Agreement [Member] \| Maximum [Member]
Liquidity (Details) [Line Items]
Aggregate offering price		30,000
Initial Public Offering [Member]
Liquidity (Details) [Line Items]
Sale of common stock shares (in Shares)	2,500,000
Public offering price, per share (in Dollars per share)	$ 10.00
Aggregate offering price	$ 23,100
Underwriting expenses	$ 1,900
ATM Offering Program [Member]
Liquidity (Details) [Line Items]
Offering program common stock value		$ 10,000

XML 32 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - Schedule of potentially issuable shares - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Summary of Significant Accounting Policies (Details) - Schedule of potentially issuable shares [Line Items]
Total	5,781,596	5,075,199
Stock options [Member]
Summary of Significant Accounting Policies (Details) - Schedule of potentially issuable shares [Line Items]
Total	3,655,549	3,417,000
Warrants [Member]
Summary of Significant Accounting Policies (Details) - Schedule of potentially issuable shares [Line Items]
Total	2,126,047	1,658,199

- Definition

Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 54
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2603-109256

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 44
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2062-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1828-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2600-109256

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2597-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 48
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2538-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 48
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2538-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 51
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2574-109256

+ Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

Research and Development Activity (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
Research and Development Activity (Details) - USD ($)	Oct. 03, 2017	Mar. 31, 2021	Dec. 31, 2020
Research and Development Activity (Details) [Line Items]
Common stock issued (in Shares)		14,932,638	13,481,283
License fee, description		In exchange for the license agreement, the Company paid UCLB an initial license fee of $10,000 and shall pay annual licensing fees of approximately $13,000 per year for the remaining term of the agreement. The Company will pay UCLB a royalty of 3-3.5%% of the net sales value (as defined in the agreement) of all licensed products sold or used by the Company. In the event the Company sub-licenses the technology and know-how, the Company will pay UCLB a royalty of twelve (12) percent of consideration (cash or non-cash) received by the Company in relation to the development or sub-licensing of any of the technology and know-how.
Research and Development Expense [Member] \| UNITED KINGDOM
Research and Development Activity (Details) [Line Items]
Research and development tax credit receivable		$ 1,104,000	$ 833,000
Reimbursements of research and development tax credit		0
Research and Development Expense [Member] \| AUSTRALIA
Research and Development Activity (Details) [Line Items]
Research and development tax credit receivable		1,086,000	$ 853,000
Reimbursements of research and development tax credit		0
Xencor, Inc. License Agreement [Member]
Research and Development Activity (Details) [Line Items]
Non refundable fee	$ 100,000
Common stock issued (in Shares)	1,585,000
Common stock with fair value on discounted cash flow	$ 12,221,000
Fair value of warrants	$ 4,193,000
Common stock equal to fully diluted shares to purchase with fair value	10.00%
Aggregate purchase price for exercise of option pro-rated for any partial exercise	$ 10,000,000
In-process research and development		$ 16,514,000
Inkmune License Agreement [Member]
Research and Development Activity (Details) [Line Items]
Percentage of licensor royalty patent grant		1.00%
University of Pittsburg License Agreement [Member]
Research and Development Activity (Details) [Line Items]
Percentage of net sales to pay royalties		2.50%
Immune Ventures to Inmune Bio [Member]
Research and Development Activity (Details) [Line Items]
Agreement expiry period, description		The PITT Agreement expires upon the earlier of: (i) expiration of the last claim of the Patent Rights (as defined in the PITT Agreement) forming the subject matter of the PITT Agreement; or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037).

XML 34 R23.htm IDEA: XBRL DOCUMENT

Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights - Inkmune License Agreement [Member] - Immune Ventures LLc [Member] - Patents [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($)
Each Phase I initiation [Member]
Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights [Line Items]
Payment method of milestone payments	$ 25
Each Phase II initiation [Member]
Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights [Line Items]
Payment method of milestone payments	250
Each Phase III initiation [Member]
Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights [Line Items]
Payment method of milestone payments	350
Each NDA/EMA filing [Member]
Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights [Line Items]
Payment method of milestone payments	1,000
Each NDA/EMA awarded [Member]
Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights [Line Items]
Payment method of milestone payments	$ 9,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

Research and Development Activity (Details) - Schedule of consideration of annual maintenance fees under the PITT agreement - University of Pittsburg License Agreement [Member] - Annual Maintenance Fees [Member] $ in Thousands	Mar. 31, 2021 USD ($)
June 26 of each year 2021-2022 [Member]
Research and Development Activity (Details) - Schedule of consideration of annual maintenance fees under the PITT agreement [Line Items]
Annual maintenance fees until first commercial sale	$ 5
June 26 of each year 2023-2024 [Member]
Research and Development Activity (Details) - Schedule of consideration of annual maintenance fees under the PITT agreement [Line Items]
Annual maintenance fees until first commercial sale	10
June 26 of each year 2025 until first commercial sale [Member]
Research and Development Activity (Details) - Schedule of consideration of annual maintenance fees under the PITT agreement [Line Items]
Annual maintenance fees until first commercial sale	$ 25

XML 36 R25.htm IDEA: XBRL DOCUMENT

Research and Development Activity (Details) - Schedule of licensee required to make milestone payments - Immune Ventures to Inmune Bio [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($)
Each Phase I initiation [Member]
Research and Development Activity (Details) - Schedule of licensee required to make milestone payments [Line Items]
Payment method of milestone payments	$ 50
Each Phase III initiation [Member]
Research and Development Activity (Details) - Schedule of licensee required to make milestone payments [Line Items]
Payment method of milestone payments	500
First commercial sale of product making use of licensed technology [Member]
Research and Development Activity (Details) - Schedule of licensee required to make milestone payments [Line Items]
Payment method of milestone payments	$ 1,250

XML 37 R26.htm IDEA: XBRL DOCUMENT

Lease (Details)	3 Months Ended
Lease (Details)	Mar. 31, 2021 USD ($)
Lease (Details) [Line Items]
Lease term	61 months
Description of extend lease term	The lessor may extend its lease for an additional 5 years, and, if it does, the Company may also extend its sublease for 5 years.
General and Administrative [Member]
Lease (Details) [Line Items]
General and administrative expenses	$ 13,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

Lease (Details) - Schedule of right-of-use assets and liabilities for operating lease - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Schedule of right-of-use assets and liabilities for operating lease [Abstract]
Right-of-use asset – related party	$ 147	$ 156
Operating lease, current liability – related party	23	34
Long-term operating lease liability – related party	116	$ 126
Total lease liability	$ 139
Weighted-average remaining lease term	3 years 73 days
Weighted-average discount rate	10.00%

XML 39 R28.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($)	3 Months Ended
Related Party Transactions (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
UCL Consultants Limited [Member]
Related Party Transactions (Details) [Line Items]
Amount of company owed to UCL Consultants Limited	$ 10,000		$ 34,000
Prepaid expenses	15,000		$ 0
Payment for medical research performed expense	88,000	$ 0
Clinical Trial and Consulting Services [Member]
Related Party Transactions (Details) [Line Items]
Payment for medical research performed expense	0	$ 79,000
Capital contribution	$ 216,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - USD ($)		1 Months Ended				3 Months Ended
Stockholders' Equity (Details) - USD ($)	May 15, 2019	Jan. 31, 2021	Jan. 20, 2020	Oct. 31, 2017	Jun. 30, 2017	Mar. 31, 2021	Mar. 31, 2020	Jul. 31, 2020	Feb. 28, 2019
Stockholders' Equity (Details) [Line Items]
Issuance of value						$ 28,446,000
Amount of sale						45,000,000
Discount rate		0.78%
Minimum volatility rate		113.00%
Maximum volatility rate		114.00%
Expected dividends		$ 0
Stock-based compensation expense						0.9
Unrecognized compensation cost						$ 7.3
Weighted-average period						2 years 262 days
Warrant, description						In connection with the Company’s initial public offering in February 2019, the Company issued warrants to the placement agents to purchase the Company’s common stock at an exercise price of $9.60 per common share, which warrants are exercisable until December 19, 2023.
Warrants are outstanding (in Shares)						19,792
Warrants intrinsic value						$ 205,000
Percentage of common stock				10.00%
Intrinsic value of warrant						$ 14.6
Expiration date					Jun. 30, 2022
Warrants exercised (in Shares)						11,875
Cash proceeds						$ 18,000
Shareholder rights agreement, description						the Company one one-thousandth of a share of a newly designated series of preferred stock, Series A Junior Participating Preferred Stock, par value $0.001 per share, of the Company, at an exercise price of $300.00 per one one-thousandth of a Series A Junior Participating Preferred Share, subject to adjustment. Subject to various exceptions, the Rights become exercisable in the event any person (excluding certain exempted or grandfathered persons) becomes the beneficial owner of twenty percent or more of the Company’s common stock without the approval of the Board.
Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Expected life		6 years
Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Expected life		6 years 3 months
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Issuance of shares (in Shares)						1,439,480
Issuance of value						$ 2,000
Number of common stock sold (in Shares)			220,000
Amount of sale			$ 1.0
Warrant [Member]
Stockholders' Equity (Details) [Line Items]
Number of common stock sold (in Shares)					31,667,000,000
Exercise price (in Dollars per share)								$ 1.50	$ 9.60
Xencor License Agreement [Member]
Stockholders' Equity (Details) [Line Items]
Warrants are outstanding (in Shares)						34,835
Warrants intrinsic value						$ 79,000
Share-based Payment Arrangement, Option [Member]
Stockholders' Equity (Details) [Line Items]
Stock-based compensation expense							$ 0.7
Lincoln Park [Member]
Stockholders' Equity (Details) [Line Items]
Description of sale of stock	Under the terms and subject to the conditions of the securities purchase agreement, the Company had the right to sell to Lincoln Park, and Lincoln Park was obligated to purchase, up to $20.0 million in shares of the Company’s common stock, subject to certain limitations, over the 24-month period that commenced on May 15, 2019.
Lincoln Park [Member] \| Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Sale of value	$ 20,000,000
Issuance of shares (in Shares)							196,000
Issuance of value							$ 1.0
2020 ATM Program [Member]
Stockholders' Equity (Details) [Line Items]
Sale of value						$ 28.4
Number of common stock sold (in Shares)						1,439,480
Amount of sale						$ 29.0
BTIG's Commission [Member]
Stockholders' Equity (Details) [Line Items]
Amount of sale						$ 582,000
Initial public offering [Member]
Stockholders' Equity (Details) [Line Items]
Purchase of shares (in Shares)		198,549
Aggregated fair value of stock options (in Shares)		4.2

XML 41 R30.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Schedule of stock option activity $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($) $ / shares shares
Schedule of stock option activity [Abstract]
Number of shares, Outstanding \| shares	3,457,000
Weighted- average Exercise Price, Outstanding \| $ / shares	$ 5.82
Weighted-average Remaining Contractual Term (years), Outstanding	8 years 18 days
Aggregate Intrinsic Value, Outstanding \| $	$ 39,405
Number of shares, Options granted \| shares	198,549
Weighted- average Exercise Price, Options granted \| $ / shares	$ 24.82
Number of shares, Options exercised \| shares
Weighted- average Exercise Price, Options exercised \| $ / shares
Number of shares, Options cancelled \| shares
Weighted- average Exercise Price, Options cancelled \| $ / shares
Number of shares, Outstanding \| shares	3,655,549
Weighted- average Exercise Price, Outstanding \| $ / shares	$ 6.85
Weighted-average Remaining Contractual Term (years), Outstanding	7 years 332 days
Aggregate Intrinsic Value, Outstanding \| $	$ 20,945
Number of shares, Exercisable at September 30, 2020 \| shares	2,415,889
Weighted- average Exercise Price, Exercisable at September 30, 2020 \| $ / shares	$ 6.54
Weighted-average Remaining Contractual Term (years), Exercisable at September 30, 2020	7 years 153 days
Aggregate Intrinsic Value, Exercisable at September 30, 2020 \| $	$ 12,906

XML 42 R31.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Schedule of stock-based compensation expense - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Research and development [Member]
Stockholders' Equity (Details) - Schedule of stock-based compensation expense [Line Items]
Total	$ 186	$ 139
General and administrative [Member]
Stockholders' Equity (Details) - Schedule of stock-based compensation expense [Line Items]
Total	713	543
Total [Member]
Stockholders' Equity (Details) - Schedule of stock-based compensation expense [Line Items]
Total	$ 899	$ 682

XML 43 R32.htm IDEA: XBRL DOCUMENT

Collaborative Agreements (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
Collaborative Agreements (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Mar. 31, 2020	Mar. 31, 2021	Dec. 31, 2020
Collaborative Agreements (Details) [Line Items]
Grand award,description	the Company was awarded a grant of up to $2.9 million from the National Institutes of Health (“NIH”). The grant will support a Phase 2 study of XPro1595 in patients with treatment resistant depression. As of March 31, 2021, the Company has not received any proceeds pursuant to this grant.	During 2020, the Company was awarded a $0.5 million grant from the Amyotrophic Lateral Sclerosis (“ALS”) Association to fund a study of the efficacy of XPro1595 to reverse ALS in vitro and to fund a study of the efficacy of XPro1595 to protect against ALS model phenotypes in vivo.
Grants received		$ 300	$ 100
Deferred liabilities			591	$ 190
ALS [Member]
Collaborative Agreements (Details) [Line Items]
Deferred liabilities			$ 200	$ 100

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 101 272 1 false 44 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://inmunebio.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://inmunebio.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated statements of operations and comprehensive loss (Unaudited) Sheet http://inmunebio.com/role/ConsolidatedIncomeStatement Consolidated statements of operations and comprehensive loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statement of Changes in Stockholders??? Equity (Unaudited) Sheet http://inmunebio.com/role/ShareholdersEquityType2or3 Consolidated Statement of Changes in Stockholders??? Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://inmunebio.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Organization and Description of Business Sheet http://inmunebio.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 7 false false R8.htm 007 - Disclosure - Liquidity Sheet http://inmunebio.com/role/Liquidity Liquidity Notes 8 false false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://inmunebio.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Research and Development Activity Sheet http://inmunebio.com/role/ResearchandDevelopmentActivity Research and Development Activity Notes 10 false false R11.htm 010 - Disclosure - Lease Sheet http://inmunebio.com/role/Lease Lease Notes 11 false false R12.htm 011 - Disclosure - Related Party Transactions Sheet http://inmunebio.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 012 - Disclosure - Stockholders' Equity Sheet http://inmunebio.com/role/StockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 013 - Disclosure - Collaborative Agreements Sheet http://inmunebio.com/role/CollaborativeAgreements Collaborative Agreements Notes 14 false false R15.htm 014 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://inmunebio.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://inmunebio.com/role/SummaryofSignificantAccountingPolicies 15 false false R16.htm 015 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://inmunebio.com/role/SummaryofSignificantAccountingPolicies 16 false false R17.htm 016 - Disclosure - Research and Development Activity (Tables) Sheet http://inmunebio.com/role/ResearchandDevelopmentActivityTables Research and Development Activity (Tables) Tables http://inmunebio.com/role/ResearchandDevelopmentActivity 17 false false R18.htm 017 - Disclosure - Lease (Tables) Sheet http://inmunebio.com/role/LeaseTables Lease (Tables) Tables http://inmunebio.com/role/Lease 18 false false R19.htm 018 - Disclosure - Stockholders' Equity (Tables) Sheet http://inmunebio.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://inmunebio.com/role/StockholdersEquity 19 false false R20.htm 019 - Disclosure - Liquidity (Details) Sheet http://inmunebio.com/role/LiquidityDetails Liquidity (Details) Details http://inmunebio.com/role/Liquidity 20 false false R21.htm 021 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of potentially issuable shares Sheet http://inmunebio.com/role/ScheduleofpotentiallyissuablesharesTable Summary of Significant Accounting Policies (Details) - Schedule of potentially issuable shares Details http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesTables 21 false false R22.htm 022 - Disclosure - Research and Development Activity (Details) Sheet http://inmunebio.com/role/ResearchandDevelopmentActivityDetails Research and Development Activity (Details) Details http://inmunebio.com/role/ResearchandDevelopmentActivityTables 22 false false R23.htm 023 - Disclosure - Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights Sheet http://inmunebio.com/role/ScheduleofmilestonepaymentsinconsiderationforthepatentrightsTable Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights Details http://inmunebio.com/role/ResearchandDevelopmentActivityTables 23 false false R24.htm 024 - Disclosure - Research and Development Activity (Details) - Schedule of consideration of annual maintenance fees under the PITT agreement Sheet http://inmunebio.com/role/ScheduleofconsiderationofannualmaintenancefeesunderthePITTagreementTable Research and Development Activity (Details) - Schedule of consideration of annual maintenance fees under the PITT agreement Details http://inmunebio.com/role/ResearchandDevelopmentActivityTables 24 false false R25.htm 025 - Disclosure - Research and Development Activity (Details) - Schedule of licensee required to make milestone payments Sheet http://inmunebio.com/role/ScheduleoflicenseerequiredtomakemilestonepaymentsTable Research and Development Activity (Details) - Schedule of licensee required to make milestone payments Details http://inmunebio.com/role/ResearchandDevelopmentActivityTables 25 false false R26.htm 026 - Disclosure - Lease (Details) Sheet http://inmunebio.com/role/LeaseDetails Lease (Details) Details http://inmunebio.com/role/LeaseTables 26 false false R27.htm 027 - Disclosure - Lease (Details) - Schedule of right-of-use assets and liabilities for operating lease Sheet http://inmunebio.com/role/ScheduleofrightofuseassetsandliabilitiesforoperatingleaseTable Lease (Details) - Schedule of right-of-use assets and liabilities for operating lease Details http://inmunebio.com/role/LeaseTables 27 false false R28.htm 028 - Disclosure - Related Party Transactions (Details) Sheet http://inmunebio.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://inmunebio.com/role/RelatedPartyTransactions 28 false false R29.htm 029 - Disclosure - Stockholders' Equity (Details) Sheet http://inmunebio.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://inmunebio.com/role/StockholdersEquityTables 29 false false R30.htm 030 - Disclosure - Stockholders' Equity (Details) - Schedule of stock option activity Sheet http://inmunebio.com/role/ScheduleofstockoptionactivityTable Stockholders' Equity (Details) - Schedule of stock option activity Details http://inmunebio.com/role/StockholdersEquityTables 30 false false R31.htm 031 - Disclosure - Stockholders' Equity (Details) - Schedule of stock-based compensation expense Sheet http://inmunebio.com/role/ScheduleofstockbasedcompensationexpenseTable Stockholders' Equity (Details) - Schedule of stock-based compensation expense Details http://inmunebio.com/role/StockholdersEquityTables 31 false false R32.htm 032 - Disclosure - Collaborative Agreements (Details) Sheet http://inmunebio.com/role/CollaborativeAgreementsDetails Collaborative Agreements (Details) Details http://inmunebio.com/role/CollaborativeAgreements 32 false false All Reports Book All Reports inmb-20210331.xml inmb-20210331.xsd inmb-20210331_cal.xml inmb-20210331_def.xml inmb-20210331_lab.xml inmb-20210331_pre.xml http://xbrl.sec.gov/country/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true ZIP 49 0001213900-21-024692-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-21-024692-xbrl.zip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end